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ABSTRACT
Obesity is a global epidemic characterized by an expansion of adipose tissue. Adipose
tissue, composed of adipocytes and a stromal vascular fraction, is an endocrine organ that regulates
whole body homeostasis. Obesity leads to the dysregulation of adipocytes and is often associated
with increased susceptibility to metabolic diseases such as Type II diabetes mellitus (T2DM).
Understanding the mechanisms by which adipocyte function and development are regulated is
crucial. Mitochondrial pyruvate carriers (MPCs) are transmembrane proteins that transport
pyruvate from the cytosol into the mitochondrial matrix to generate acetyl CoA. Although MPCs
have been studied extensively, their roles in adipocytes are not known. To study the role of MPCs
in adipocytes, we assessed the requirement of MPC1 for adipogenesis, the expression of MPCs in
adipose tissue, and the nutritional regulation of MPCs during diet-induced obesity (DIO). Our
novel studies show that MPCs are not required for adipogenesis but are highly expressed in brown
adipose tissue (BAT), and that MPC expression levels are regulated by DIO in the BAT of male
mice. KAT8 is a lysine acetyltransferase that plays a role in DNA damage repair, apoptosis, and
tumorigenesis. Although KAT8 is an important component of many cellular processes, its role in
adipocytes is unknown. Notably, a large genome-wide association study identified KAT8 as part
of a novel locus that significantly contributed to variations in body mass index and other metabolic
phenotypes. Hence, we examined the expression and regulation of KAT8 in adipocytes. In vitro
experiments revealed that KAT8 expression was required for adipogenesis but did not affect
turnover rates of peroxisome proliferator-activated receptor g (PPARg) and fatty acid synthase
(FASN). Our novel in vivo data demonstrates that KAT8 is highly expressed at the protein level in
white adipose tissue (WAT) depots, upregulated by DIO in the iWAT and gWAT of male mice,
and upregulated by refeeding after fasting in adipose tissue (AT) depots. We have observed that

xi

KAT8 expression is required for adipogenesis in vitro and is nutritionally regulated in WAT in
vivo. Collectively, these studies have identified an epigenetic modifier that plays a previously
unidentified role in adipocyte development and function.

xii

CHAPTER 1. GENERAL INTRODUCTION
1.1 Adipocytes
Obesity is a disease with increasing prevalence that is characterized by an excess
accumulation of adipose tissue. In the past two decades, obesity prevalence has increased from
30.5% to 42.4% [1], fueling a parallel increase in associated metabolic diseases such as type 2
diabetes (T2DM). According to the CDC, diabetes is the 7th leading cause of death, and over 34
million people have diabetes in the United States [2]. Adipose tissue, once thought to be nothing
more than a site for energy storage in the form of triacylglycerols (TAGs), is now recognized as a
complex endocrine organ with essential roles in energy homeostasis and metabolism. Therefore,
the coupled epidemics of obesity and metabolic dysfunction have driven intensive research to
explore the roles and functions of adipocytes and adipose tissue [3–5].
Adipose tissue is composed of adipocytes and a stromal vascular fraction comprised of
preadipocytes, fibroblasts, endothelial cells, macrophages, and leukocytes. Adipose tissue is
distributed throughout the body and expands to accommodate excess lipid [6]. Expansion occurs
by hypertrophy, hyperplasia, or a combination of both processes. In humans, there are two general
types of adipose tissue: white adipose tissue (WAT) and brown adipose tissue (BAT). Yet, it
should be noted that a new type of adipocyte called beige or brite adipocytes have been identified
and extensively studied in the last decade. Beige adipocytes are found in WAT and have enriched
expression of BAT markers [7,8].
Brown adipocytes in BAT are characterized by their multilocular morphology and high
mitochondrial content, which contributes to its brown color. BAT’s highly specialized role is to
generate heat through non-shivering thermogenesis [5,6]. This process is mediated by uncoupling
protein 1 (UCP1), which uncouples fatty acid oxidation from oxidative phosphorylation and ATP
synthesis by dissipating the proton gradient across the mitochondrial membrane as heat. Brown
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adipose tissue (BAT) is relatively abundant in neonatal stages and was once thought to be
completely replaced by white adipose tissue (WAT) in humans with aging [6,9]. More recent
studies, however, have revealed that BAT is present in adults. These studies reveal that BAT is
metabolically active in the cervical, axillary, and paraspinal areas, and that it may account for 12% of the total fat in humans [10–13].
WAT is responsible for the synthesis and storage of TAGs during periods of energy
surplus, and for the hydrolysis of TAGs via lipolysis to generate free fatty acids (FFAs) and
glycerol during periods of energy deficiency [3,14]. WAT makes up the majority of the adipose
tissue volume in the human body and increases in volume with age. WAT is categorized in two
ways: visceral WAT and subcutaneous WAT. Visceral WAT is located in the abdominal cavity
and lines the internal organs. Visceral WAT represents approximately 6-20% of the total body fat,
and is typically more abundant in males than females [15]. There are four types of visceral WAT
in humans: mesenteric, omental, peritoneal, and perirenal [6]. Disruption of homeostasis in
visceral WAT can lead to increased mortality and metabolic complications, such as insulin
resistance, type 2 diabetes, and hyperlipidemia [6,16–18]. Accretion of adipose tissue
predominantly localized to visceral depots is often referred to as apple-shaped fat distribution.
On the other hand, subcutaneous adipose tissue is located just below the skin. It comprises
approximately 80-90% of the total body fat in lean, healthy individuals, and is more abundant in
females [13,15]. In contrast to visceral WAT, subcutaneous WAT has been suggested to have a
protective metabolic role [19]. Increased distribution of subcutaneous WAT in the gluteofemoral
regions, referred to as pear-shaped distribution, has been associated with a lower risk of developing
type 2 diabetes and with improved insulin sensitivity. Transplantation of subcutaneous WAT into
visceral epididymal WAT cavities of C57BL/6 mice resulted in reduced body weight, fat mass,
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glucose levels, and insulin levels [20]. When the storage capacity of subcutaneous WAT is
exceeded during states of positive energy balance, lipid is then displaced and ectopically deposited
in areas outside of the adipose tissue, which can have detrimental metabolic effects [13].
Adipocytes have several features that are critical to their effects on whole-body metabolic
function. These include the storage and release of lipids, the secretion of adipokines, and the ability
to respond to insulin. Mature white adipocytes are unilocular cells containing a single large lipid
droplet that occupies most of the cell, with the nucleus and other organelles pushed against the
plasma membrane [21]. The primary function of adipocytes is to store lipid. Adipocytes regulate
both lipid synthesis (lipogenesis) and lipid catabolism (lipolysis) in response to the body’s energy
status [22]. When substrate availability is high, such as in the fed state, lipids accumulate, in the
form of TAGs, in adipocytes via two processes: lipogenesis and fatty acid (FA) uptake [22].
Conversely, lipolysis is the process by which TAGs are broken down into free fatty acids (FFAs)
and glycerol via a series of lipases [22] in conditions of low substrate availability. In addition to
lipid metabolism, adipocytes exclusively synthesize and secrete three vital adipokines: leptin
[23,24], adiponectin [25], and resistin [26]. Leptin, the first adipokine to be characterized, is
referred to as the “satiety hormone” because it is secreted from adipocytes and signals to the
hypothalamus to decrease food intake and

increase energy expenditure [27]. Adiponectin,

identified in 1995 as adipocyte complement-related protein of 30 kDa (Acrp30) [25], positively
regulates adipogenesis, maintains insulin sensitivity, and has anti-inflammatory effects [28].
Resistin, the most recently discovered adipocyte hormone, induces insulin resistance [28].
Resistin, which is derived from adipocytes in mice and from macrophages in humans, mediates
the same metabolic and inflammatory responses in both species [28]. Disruptions in any adipocyte
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functions result in metabolic dysfunctions commonly associated with obesity and metabolic
syndrome. Hence, it is important to have properly functioning adipocytes.
Metabolic syndrome defines a cluster of cardiometabolic risk factors that increase
susceptibility for metabolic diseases such as type 2 diabetes mellitus (T2DM), heart disease, and
stroke [29,30]. These risk factors include hypertension, hyperglycemia, excess abdominal fat, and
abnormal cholesterol and TG levels [30]. Having three or more of these risk factors greatly
increases the occurrence of diseases such as T2DM. T2DM, characterized by insulin resistance
and hyperglycemia [31], is the most common form of diabetes and accounts for an estimated 95%
of all diabetes diagnoses [2]. Factors associated with increased susceptibility of developing T2DM
are obesity, genetic predisposition, aging, and physical inactivity [32]. It is well-known that excess
adipose tissue is directly associated with insulin resistance, and that glucose homeostasis is
dependent upon the functionality of adipose tissue. This information highlights the need to study
adipose tissue dysfunction and the mechanisms by which fat contributes to obesity-related T2DM.
The excessive expansion of adipose tissue observed in obesity is driven by an increase in
the generation of new adipocytes (hyperplasia) or an increase in adipocyte size (hypertrophy), or
by a combination of both [6]. Hyperplastic expansion of adipose tissue, predominant in
subcutaneous WAT, is characterized by an increase in differentiation of adipocyte precursor cells
into preadipocytes and then adipocytes [6]. Expansion due to hypertrophy often results in
abnormalities associated with necrosis, such as macrophage infiltration [33], increased production
and secretion of inflammatory cytokines, adipose tissue hypoxia, and elevated basal lipolysis rates
[34–36]. However, hypertrophic adipocytes that are associated with increased adipose tissue mass
are not always associated with metabolic dysfunction.
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The importance of adipogenesis in metabolic health is demonstrated by the fact that
impaired adipocyte differentiation is often associated with insulin resistance and metabolic disease
states [37]. Indeed, the thiazolidenediones (TZDs), a class of PPARg agonists which act by
enhancing adipogenesis are known to have potent insulin-sensitizing effects [38,39]. To fully
understand how adipocytes contribute to metabolic dysfunction, it is necessary to understand the
development of adipocytes. Adipogenesis is a tightly regulated cellular process by which
adipocytes are developed from adipocyte precursor cells, or preadipocytes, via cellular
differentiation. This process is driven by peroxisome proliferator-activated receptor g (PPARg ),
the master regulator of adipogenesis, in conjunction with sterol regulatory element-binding
transcription factor 1c (SREBP1c) to enhance the expression of lipogenic genes [6,40].
Adipogenesis is transcriptionally regulated by PPARg, which is required and is the principal
regulator of adipogenesis both in vivo and in vitro [28,41]. PPARg has also been reported to induce
the expression of signal transducers and activators of transcription 5A and B (STAT5A and B),
which further promote adipogenesis [42,43]. In addition, CCAAT/enhancer-binding proteins
(C/EBPs) are transcription factors that regulate proliferation and differentiation, and C/EBP α, β
and δ have been shown to be regulators of adipogenesis [44]. Moreover, C/EBPβ and C/EBPδ
work in conjunction during early stages of adipogenesis to induce expression of C/EBPα and
PPARg to promote adipocyte differentiation [28]. Although many transcriptional factors have been
identified as regulators of adipogenesis, other proteins are likely to directly or indirectly regulate
adipogenesis.
1.2 Mitochondrial Pyruvate Carriers
Pyruvate is an essential metabolite, and transport of pyruvate into the mitochondria is vital
for metabolic processes such as glycolysis [45]. Cellular pyruvate can be reduced to lactate by
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lactate dehydrogenase (LDH) to generate nicotinamide adenine dinucleotide (NAD+), which is
required for glycolysis to produce ATP, or it can be transported into the mitochondrial matrix
where it is oxidized to acetyl CoA by the pyruvate dehydrogenase complex (PDC) before entering
into the TCA cycle [45]. Mitochondrial pyruvate carriers (MPCs) are transmembrane proteins
located on the inner mitochondrial membrane that transport pyruvate from the cytosol into the
mitochondrial matrix [46]. In 1970, a mitochondrial pyruvate transporter was first identified in rat
liver and described as a translocator that couples hydroxy ion counterflux to proton symport to
transport pyruvate across the mitochondrial matrix [47]. Although the mitochondrial pyruvate
transporter was discovered in 1970, it wasn’t until 2012 that MPC proteins were characterized
[48]. Bricker et. al. identified two MPC isoforms, MPC1 and MPC2 (also known as Brp44L and
Brp44, respectively), that form a heterodimer to actively transport pyruvate into the inner
mitochondrial membrane in mammals and Drosophila [46,48]. While there are only two isoforms
in mammals and flies, three isoforms have been found in Saccharomyces cerevisiae: MPC1,
MPC2, and MPC3 [48]. In humans and flies, MPC1 and MPC2 act in a codependent manner, as
the loss or deletion of one protein results in the loss of the other MPC due to destabilization of the
MPC1:MCP2 complex [48–50]. The use of MPC1 mutants demonstrated that the dimerization of
MPC1 and MPC2 in the inner mitochondrial membrane is essential for pyruvate uptake into the
mitochondria of Saccharomyces cerevisiae for generation of acetyl CoA [48].
MPC1 expression may also play a role in cancer metabolism. An increase in the rate of
glycolysis is one of the distinct metabolic features present in cancer cells, along with mitochondrial
reprogramming and a down regulation of lipid metabolism [51]. The Warburg effect, characterized
by a decrease in pyruvate oxidation, is one of the hallmarks of the metabolic reprogramming in
cancer cells [52]. Schell et. al. have implicated the reduced expression of MPCs as a culprit in
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cancer cell development via its involvement in the Warburg effect [52]. The MPC1 locus, but not
MPC2 locus, was found to be within a region that is frequently deleted in cancer, resulting in very
low expression of MPC1 in cancer cells [52]. In human gastric cancer (GC) tissue and cells, MPC1
expression was significantly downregulated and was associated with advanced tumor node
metastasis (TNM) [53]. In addition, reintroduction of MPC1 into colon cancer cell lines via
retroviral expression resulted in stabilization of the MPC complex and enhanced pyruvate
oxidation to inhibit cell proliferation [52]. These lines of evidence suggest that MPCs could be
targets for cancer therapeutics.
Much is known about pyruvate transport in the heart. Shearman et. al. discovered that
MPCs were expressed in the heart, and showed that MPCs were as abundant in the heart as in the
liver [54]. MPC2 deficiency in heart mitochondria of C57BL6 mice resulted in reduced pyruvate
utilization and pyruvate/malate-stimulated respiration [55]. Reduced pyruvate oxidation and
mitochondrial metabolism have been witnessed in chronic heart failure [56–59] and have been
suspected to be due to reductions in PDH activity [60]. Collectively, these studies suggest that
enhancement of MPC import could potentially improve cardiac function.
Panic et. al. reported that the loss of MPC1 in BAT of C57BL6 mice resulted in impaired
thermogenesis and increased sensitivity to cold exposure [61]. In addition, a BAT-specific deletion
of MPC1 reduced core body temperature and impaired glucose metabolism [61]. In a liver-specific
MPC2 knockout mouse model, the loss of MPC2 impaired pyruvate oxidation for generation of
tricarboxylic acid (TCA) cycle intermediates and glucose [49]. Hepatic gluconeogenesis is
enhanced in the event of insulin deficiency and contributes to hyperglycemia associated with
diabetes [49]. Thus, MPC2 may contribute to diabetes via its role in hepatic glucose output.
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Although data pertaining to the functions of MPCs are abundant, very little is known about their
regulation and roles in adipocytes.
1.3 Lysine Acetyltransferase 8 (KAT8)
Histone acetyltransferases (HATs) are responsible for transferring acetyl groups from
acetyl CoA to specific lysine residues on their target substrates, that are often histones. Histone
acetylation, which modulates chromatin structure and gene expression, is primarily controlled by
HATs and reversed by histone deacetylases (HDACs). However, HATs can acetylate other
proteins besides histones and are now more commonly referred to as lysine acetyltransferases, or
KATs. One member of the KAT family, KAT8 has been reported to play a role in many cellular
functions.
KAT8 was initially described as males-absent-on-the-first (MOF) in Drosophila
melanogaster, because it is a male-specific protein that exhibits lethality when mutated in males
[62]. In Drosophila, KAT8 contributes to two regulatory complexes that both play roles in
activation of target gene transcription. The first is the male-specific lethal (MSL) complex, which
is a chromatin remodeling complex assembled only in male flies [63]. This complex consists of
KAT8 alongside four other core components: MSL1, MSL2, MSL3 and MLE (maleless helicase)
as well as two long non-coding RNAs on the X chromosome (roX1 and roX2) [64]. The second,
non-specific lethal (NSL) complex, is present in both males and females and modulates
transcription of housekeeping genes [63]. This complex consists of KAT8 and five other core
components: NSL1, NSL2, NSL3, methyl binding domain-related 2 (MBDR2) and microspherule
protein 2 (MCRS2) [62]. In each of the mammalian species in which KAT8 is present, the MSL
complex is conserved [63].
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KAT8 is also a member of the MYST family, named for its original members MOZ,
Ybf2/Sas3, Sas2, and Tip60 [65]. The MYST family proteins are characterized by their roles in
post-translational modifications of histone and chromatin remodeling in eukaryotes [66]. Proteins
in the MYST group all possess the conserved MYST domain, which consists of an acetyl CoAbinding motif as well as a CCHC-type zinc finger to mediate substrate recognition [66]. Functional
domains also present in KAT8 include a N-terminal chromodomain (CHD) which plays a role in
RNA binding [67,68], a HAT domain, and a chromobarrel domain (CBD) at the C-terminal which
modulates HAT activity [62,63]. The N-terminal domains are responsible for the modulation of
substrate binding [62]. KAT8 has been reported to have many functions and interactions with a
variety of substrates [69–78].
One of KAT8’s well-studied targets in mammalian cells is Histone 4 Lysine 16 (H4K16),
via the MSL complex or NSL complex [69]. KAT8 can also acetylate H4K5 and H4K8 via the
NSL complex [69]. Many studies have shown that disruption of KAT8 expression and function
can result in irregularities in cell cycle, cell proliferation, gene transcription, DNA damage repair,
early embryonic development, or promotion of tumorigenesis, and autophagy [69,70,77–79].
Although histones are the primary targets for KAT8 activity, KAT8 has been shown to acetylate
other substrates. Acetylation of LSD1 (lysine-specific histone demethylase 1) by KAT8 reduced
tumorigenesis [71], while KAT8-mediated acetylation of the tumor suppressor p53 has been
reported to promote cellular apoptosis in response to DNA damage [72–74]. Another study showed
that KAT8 acetylates DBC1 (deleted in breast cancer 1) and reduces DBC1’s binding affinity for
SIRT1 (sirtuin 1), a histone deacetylase, to increase SIRT1 activity [75].
In mouse embryonic fibroblast (MEF) cells, it was reported that an induction of autophagy
by amino acid starvation resulted in reduced H4K16 acetylation via the downregulation of KAT8
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[80]. This same study showed that rapamycin treatments in autophagic impaired cells could elicit
the same downregulation of H4K16 acetylation in both MEF and HeLa cells [80]. Sheikh et. al.
developed a tamoxifen-inducible KAT8 knockout in MEFs, in which the loss of KAT8 expectedly
resulted in diminished H4K16 acetylation [81]. Loss of KAT8 resulted in an arrest in cellular
proliferation, and the expression of genes associated with the progression of the cell cycle was
blunted [81]. Loss of KAT8 in podocytes significantly downregulated pathways associated with
lysosomes, valine, leucine, and isoleucine degradation, endocytosis, and extracellular matrixreceptor interactions [81]. KAT8-deficient MEFs treated with adriamycin to induce autophagy
revealed the same pathway inhibitions [81]. Overall, these studies show that KAT8 plays a role in
cellular autophagy.
Recently, another study reports that acetylation of interferon regulatory factor 3 (IRF3) by
KAT8 suppresses antiviral innate immunity [82]. This finding is interesting because activation of
IRF3 is tightly regulated by posttranslational modifications such as phosphorylation and
ubiquitination. Phosphorylation positively regulates IRF3 activation while ubiquitination results
in degradation of IRF3. The knockdown of KAT8 in peritoneal macrophages treated with vesicular
stomatitis virus (VSV) selectively induces the expression of type I interferons (IFNs), IFNa and
IFNb [82]. KAT8-deficient mice infected with VSV also had reduced mortality rates compared
with the KAT8-sufficient mice, due to the induction of type I IFNs [82]. Immunoprecipitation
studies in HEK293T cells revealed that KAT8 suppresses type I IFN production via its direct
interaction with IRF3, which was enhanced after VSV infection. Not only does KAT8 interact
with IRF3, it promotes IRF3 acetylation at K359 without affecting IRF3 activation [82]. Overall,
this study shows that IRF3 acetylation by KAT8 regulates type-I IFN production and is enhanced
during viral infection.
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Fatty Acid Synthase (FASN), which drives fatty acid synthesis and de novo lipogenesis, has
been reported as a target of KAT8. A study conducted by Lin et al. confirmed the interaction of
KAT8 and FASN through a series of studies in HEK293T and HCT116 cells (human colorectal
cancer line) to examine FASN acetylation [76]. Immunoprecipitation experiments were performed
to screen various KAT enzymes for interaction with FAS, and KAT8 was the only one found to
immunoprecipitate with FAS, indicating a direct interaction between the two proteins [76]. In
addition, overexpression of KAT8 produced a robust decline in FASN, suggesting that KAT8
directly interacts with FASN and promotes its degradation via acetylation [76].
Gao et al. have reported that STAT5B modulates KAT8 expression binding to the MOF
promoter in 3T3-L1 cells and that this interaction was necessary to negatively regulate
adipogenesis [83]. However, there are no other studies of KAT8 in adipocytes. Interestingly,
however, a genome-wide association study (GWAS) meta-analysis identified KAT8 as 1 of 97
body mass index (BMI)-associated loci that contribute to variations in BMI [84]. The discovery of
a role for KAT8 in fat cells would be a novel finding and would enhance the field of adipocyte
biology.
The incidence of obesity and related metabolic diseases continues to rise around the world and
represents one of the greatest public health challenges of our time. It is now known that adipose
tissue has a very important role in metabolic health, and that disruption of adipocyte development
and function can drive poor metabolic outcomes in obese and insulin resistant states. Pursuing a
greater understanding of adipocyte biology is crucial to stemming the tide of metabolic dysfunction
in obesity. Studying the functions of both KAT8 and MPCs in adipocyte development and function
can provide insight into the complexity of this endocrine organ.
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CHAPTER 2. MITOCHONDRIAL PYRUVATE CARRIERS ARE NOT
REQUIRED FOR ADIPOGENESIS, BUT REGULATED BY HIGH-FAT
FEEDING IN BROWN ADIPOSE TISSUE1
2.1 Introduction
The mitochondrial pyruvate carriers (MPCs) are transmembrane proteins, found on the
inner mitochondrial membrane, that transport pyruvate from the cytosol into the mitochondrial
matrix where pyruvate is oxidized to acetyl CoA and carbon dioxide via the pyruvate
dehydrogenase complex (PDC). Acetyl CoA is utilized in the citric acid cycle to form NADH for
oxidative phosphorylation (OXPHOS) to create a proton gradient for the production of ATP via
the ATP synthase complex. There are two MPC proteins in mammals (MPC1 and MPC2), but
there are three that have been identified in Saccharomyces cerevisiae (MPC1, MPC2, and MPC3)
[45]. In mammals, MPC1 and 2 form a heterodimer to actively transport pyruvate into the
mitochondria [85]. Since MPC1 and MPC2 act in a codependent manner, the loss or deletion of
one of these proteins results in the loss of the other MPC due to destabilization [85–87]. The study
of MPC1 mutants has confirmed that dimerization of MPC1 and MPC2 in the inner mitochondrial
membrane is essential for pyruvate uptake into the mitochondria [86].
MPC1 expression may also play a role in cancer metabolism as inhibition of MPC complex
formation, via UK-5099, hinders pyruvate’s entry into the mitochondria and is associated with
increased glycolysis [88]. Increased glycolysis is a distinct metabolic feature of cancer cells, along
with mitochondrial reprogramming and decreased lipid metabolism [51]. The MPC inhibitor, 2Cyano-3-(1-phenyl-1H-inodl-3-yl)-2-propenic acid (UK-5099), binds to MPCs, which deactivates

This chapter previously appeared as: Burrell J.A., Richard A.J., King W.T., Stephens J.M. (2019). Mitochondrial
Pyruvate Carriers are not Required for Adipogenesis but are Regulated by High‐Fat Feeding in Brown Adipose
Tissue. Obesity. 28(2):293-302. doi: 10.1002/oby.22678. It is reprinted by permission of John Wiley and Sons.
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the MPC complex and inhibits pyruvate oxidation [89]. Thiazolidinediones (TZDs) inhibit MPC
in several cell types, and in skeletal muscle inhibition of MPC is associated with increased glucose
uptake and increased insulin sensitivity. Using the CRISPR/Cas9 system, a heterozygous MPC1
knockdown model was generated and these mice had reduced lipid accumulation, increased
lipolysis, enhanced fatty acid oxidation, and decreased energy expenditure [90]. During
adipogenesis, mitochondrial density is increased by 20- to 30- fold along with increases in
mitochondrial gene expression and oxidative capacity to meet increasing energy requirements [91–
95]. Insufficient or reduced mitochondrial density in tissues with a high energy demand like the
brain, heart, muscles, and endocrine organs, such as adipose tissue, are associated with disease
states [96]. Although MPCs have been studied in several cell and tissue types, the role of these
proteins in adipocyte development and their regulation in conditions of obesity is not known.
In our novel studies, we examined the requirement of MPC1 during adipocyte development
using two independent approaches. Both pharmacological inhibition of MPCs as well as siRNAmediated knockdown of MPC1 demonstrated that the expression and/or activity of MPC1 was not
required for adipogenesis in 3T3-L1 cells. To our knowledge, this is the first siRNA-mediated
MPC1 knockdown reported in 3T3-L1 cells. However, siRNA-mediated knockdown of MPC1 and
MPC2 in 832/13 β-cells resulted in impaired insulin secretion in response to glucose and
reductions in glucose-stimulated oxygen consumption [97]. We also examined the modulation of
MPC expression in both brown and white adipose tissue depots of male and female mice in a
rodent model of diet-induced obesity. Expression levels of MPC1 and MPC2 were substantially
decreased in the brown adipose tissue (BAT) of male mice following high-fat feeding, but not in
female mice under the same conditions. In conclusion, our results indicate that loss of MPC1 does
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not have any effect on adipogenesis of 3T3-L1 preadipocytes; MPC1 and 2 are highly expressed
in BAT; and MPC1 and 2 are modulated by high-fat feeding in BAT of male mice.

2.2 Materials and Methods
Animals and Diets- Four-week-old male and female C57BL/6J mice were purchased from
Jackson Laboratories (Stock #000664; Bar Harbor, ME). Animals were housed in a temperature
(22 ± 2°C)- and humidity-controlled (45–55%) room under a 12-h light/dark cycle. At six weeks
of age, mice were placed on respective diets. Mice were allowed ad libitum access to food and
water. For twelve weeks, mice had access to either LFD containing 20% kcal protein, 70% kcal
carbohydrate, and 10% kcal fat (D12450J; Research Diets, Inc. New Brunswick, NJ) or HFD
containing 20% kcal protein, 20% kcal carbohydrate, and 60% kcal fat (D12492; Research Diets,
Inc. New Brunswick, NJ). Body weights were obtained biweekly. Mice were fasted for four hours
prior to sacrifice. All animal studies were performed with approval from the Pennington
Biomedical Research Center Institutional Animal Care and Use Committee.
Animal body composition and glucose tolerance measurements- Non-fasting body
composition was measured by NMR (Bruckner Minispec) before beginning LF or HF diet
intervention at 6 weeks of age and at 19 weeks of age (after 12 weeks of LFD- or HFD-feeding).
Adiposity was calculated as total fat mass/total body weight x 100. Following a 4-hour fast,
intraperitoneal glucose tolerance tests (IPGTTs) were performed on all animals at 17 weeks of age
(10 weeks on diet). A baseline blood glucose measurement was obtained via tail nick (0 minutes),
and animals were then injected with 2.5g/kg glucose. Blood glucose measurements were obtained
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via a drop of blood collected from the tail vein at 20, 40, 60, and 120 minutes post-injection. Blood
glucose measurements were performed using a Breeze 2 glucometer (Bayer, Parsippany, NJ).
Cell culture- Murine 3T3-L1 preadipocytes were grown in Dulbecco’s Modified Eagle’s Media
(DMEM) (Sigma-Aldrich, St. Louis, MO) with 10% bovine calf serum. Two days after confluence,
the preadipocytes were induced to differentiate using a standard protocol and induction cocktail
composed of 3-isobutyl-methylxanthine, dexamethasone, insulin (MDI), and 10% characterized
fetal bovine serum (FBS) in DMEM. HyClone calf and fetal bovine serum were purchased from
Thermo Scientific (Waltham, MA) or GE Healthcare Life Sciences (Marlborough, MA). The
medium was changed every 48 – 72 hours during growth and differentiation.
Pharmacological Inhibitor (UK-5099) Treatments- 3T3-L1 preadipocytes were trypsinized and
seeded into 6-well plates at a density of 5.8 x 105 cells/cm2 in antibiotic-free 10% bovine
calf/DMEM when approximately 70% confluent in 10-cm plates. 3T3-L1 preadipocytes were
treated with 10µM UK-5099 (Sigma-Aldrich, St. Louis MO; PZ0160) added to the medium upon
seeding. Preadipocytes were induced to differentiate as described above. Cells were fed with
antibiotic-free media and treated with UK-5099 every 48 hours. Seven days after the induction of
differentiation, the cell monolayers were harvested for protein in immunoprecipitation (IP) buffer
containing 10mM Tris (pH 7.4), 150mM NaCl, 1mM EGTA, 1mM EDTA, 1% Triton X-100, 0.5%
IGEPAL CA-630, protease inhibitors (1mM phenylmethylsulfonyl fluoride, 1μM pepstatin, 50
trypsin inhibitory milliunits of aprotinin, 10μM leupeptin, 1 mM 1,10-phenanthroline), and
phosphatase inhibitors (0.2mM sodium vanadate and 100µM sodium fluoride), and for RNA in
buffer provided in the RNeasy mini kit (Qiagen, Hilden, Germany) to assess knockdown
efficiency. Three biological and technical replicates and were analyzed for each dose.
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Cytotoxicity and cell viability assays- The ToxiLight BioAssay kit (Lonza, Cologne, Germany)
was utilized according to the manufacturer’s protocol. ToxiLight 100% lysis reagent (Lonza,
Cologne, Germany) was utilized as a positive control. Cell viability was assessed by counting
trypan blue-stained cells using a hemocytometer.
Whole cell extract preparation- Cell monolayers were rinsed once with phosphate-buffered
saline (PBS) and then scraped into non-denaturing IP buffer. The whole cell extracts were stored
at -80°C before being thawed and passed through a 20-gauge needle five times. The whole cell
extract was clarified via centrifugation at 13,000 x g for 10 min at 4°C.
Small interfering RNA (siRNA)-mediated knockdown- 3T3-L1 preadipocytes were trypsinized
and re-plated in 6-well plates at a density of 5.8 x 105 cells/cm2 in antibiotic-free 10% bovine
calf/DMEM when approximately 70% confluent in 10-cm plates. Using the protocol from
Dharmacon, preadipocytes were transfected with 33nM siRNA (Dharmacon, Lafayette, CO; Nontargeting siRNA Cat #: D-001810-10-50, siRNA targeting MPC1 Cat #: L-040908-01-0005) and
the DharmaFECT Duo transfection reagent (Dharmacon, Lafayette, CO, Cat #: T-2010-03) in
OptiMEM reduced serum medium (Thermo Fisher, Waltham, MA; Cat #: 31985088). Nontargeting siRNA was used as negative control. Cells were treated with the siRNA cocktail during
initial plating and grown to confluence. Two days after confluence, cells were induced to
differentiate with the MDI-induction cocktail, as described above, and transfected again with the
siRNA cocktail. After 48 hours, the cells were treated with ¼ normal dose of insulin and
transfected once again with the siRNA cocktail. Cells were fed every 48 hours with antibioticfree media throughout the entire knockdown process. Seven days after the induction of
differentiation, the cell monolayers were harvested for protein in IP buffer, and for RNA in buffer
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provided in the RNeasy mini kit (Qiagen, Hilden, Germany) to assess knockdown efficiency.
Three biological and technical replicates were analyzed for each dose.
Respirometry- Mitochondrial function was assessed by respirometry of intact cells using a
Seahorse XFe24 Analyzer (Agilent Technologies; Santa Clara, CA). Mature 3T3-L1 adipocytes
were seeded at 1.0x105 cells per well in an XF24 specialized cell culture microplate that was coated
with 0.1% gelatin for 48 hours prior to seeding. Upon seeding, cells were incubated at 37°C
without CO2 for one hour prior to assay in XF base media (Agilent Technologies; Santa Clara,
CA) supplemented with 25mM glucose and 2mM L-glutamine at pH 7.4. After basal oxygen
consumption was measured for three cycles, 1mM sodium pyruvate ± 10µM UK-5099 was
injected into each well. After three basal measurement cycles, 1µM oligomycin, 600nM carbonyl
cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP), and 5µM rotenone/antimycin A were
serially injected, and oxygen consumption was measured for three, six, and three cycles,
respectively. After the assay was complete, cells were harvested in RIPA buffer, and protein
concentration was quantified using the bicinchoninic acid (BCA) assay kit (Sigma-Aldrich, St.
Louis, MO; Cat #: BCA1). Oxygen consumption rate was normalized to µg of protein.
Gel electrophoresis and immunoblotting- Protein content of cell extracts was quantified via
BCA assay. Samples were separated on 7.5%, 12%, or 15% sodium dodecyl sulfate (SDS)
polyacrylamide (PA) gels (acrylamide; National Diagnostics, Atlanta, GA; Cat #: EC-890) and
transferred to nitrocellulose membranes (BioRad, Hercules, CA; Cat #: 162-0115) in 25 mM Tris,
192 mM glycine, and 20% methanol. After the transfer, membrane strips were blocked in 4% nonfat milk for 1 hour at room temperature and washed with TBS-T before incubating with primary
antibodies overnight at 4°C. Strips were washed with TBS-T and then incubated with either antimouse or anti-rabbit horseradish peroxidase-conjugated secondary antibodies (Jackson
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ImmunoResearch, West Grove, PA) for 1h. Strips were washed with TBS-T and visualized with
enhanced chemiluminescence (Pierce/Thermo Scientific, Waltham, MA).
Antibodies- Anti-STAT5A (L-20; sc-1081; rabbit polyclonal), anti-adipsin (M-120; sc-50419;
rabbit polyclonal), anti-STAT3 (C-20; sc-482; rabbit polyclonal) and anti-ERK1/2 (C-16; sc-93;
rabbit polyclonal) antibodies were purchased from Santa Cruz Biotechnology (Dallas, TX). Antiadiponectin (PA1-054; rabbit polyclonal) antibody was purchased from Thermo Scientific
(Waltham, MA). Anti-MPC1 (14462S; rabbit monoclonal) and anti-MPC2 (D4I7G; rabbit
monoclonal) antibodies were purchased from Cell Signaling Technology (Danvers, MA).
RNA analysis- Total RNA from tissue samples was extracted according to TRIzol manufacturer
instructions. RNA from tissue or adipocyte monolayers was purified using the RNeasy mini kit
(Qiagen, Hilden, Germany). Ten microliters of purified RNA were used for reverse transcription
(RT) to generate cDNA according to the Applied Biosystems protocol (Applied Biosystems, Foster
City, CA; Cat #: 4368813). cDNA was quantified using the real-time quantitative PCR (qPCR)
method in a total volume of 10µL (2µL DNA and 8µL reaction master mix) using an Applied
Biosystems 7900HT System with SDS 2.4 software. qPCR was performed using Takara SYBR
premix (Takara Bio USA Inc., Madison, WI, USA) and primers from IDT (Integrated DNA
Technologies, Skokie, IL, USA). Thermal cycling conditions were as follows 2 min at 50 °C, 10
min at 95 °C, 40 cycles of 15 s at 95 °C; dissociation stage 15 s at 95 °C, 15 s at 60 °C, and 15 s
at 95 °C. Cyclophilin A (Ppia) and Non-POU domain containing octamer binding protein (NoNo)
were used as reference genes. The following mouse genes were examined by RT-qPCR:
Oxoglutarate Dehydrogenase (Ogdh), Succinate Dehydrogenase Complex Iron Sulfur Subunit B
(Sdhb), Mitochondrial Pyruvate Carrier 1 (Mpc1), Mpc2, CCAAT enhancer-binding protein alpha
(Cebpa), Peroxisome Proliferator-Activated Receptor Gamma (Pparg), Adiponectin (Adpn),
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Citrate synthase (Cs), Fatty Acid Binding Protein 4 (aP2), Fatty Acid Synthase (Fas), and Adipsin
(Cfd). Primer sequences are shown in Table 1.
Lipid Accumulation Measurement- Seven days after the induction of differentiation, cells were
fixed and stained with Oil Red O (ORO; Sigma-Aldrich, St. Louis, MO, USA) as described
previously [98].
Statistical analysis- Statistical analyses were performed using GraphPad Prism software (version
8; La Jolla, CA, USA). Differences between groups were calculated using Student’s t-tests and
two-way ANOVA. Area under the curve (AUC) calculations and standard linear regression
analyses were performed to determine correlations between MPC protein expression and adiposity
or GTT AUC. Results from studies of cultured adipocytes are shown as mean ± standard error of
the mean (SEM). Results were considered statistically significant when p < 0.05.
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Table 2.1. qPCR Primer Sequences
Gene
Cyclophilin A
(Ppia)
Non-POU
domain
containing
octamer
binding protein
(Nono)
Oxoglutarate
Dehydrogenase
(Ogdh)
Succinate
Dehydrogenase
Complex Iron
Sulfur Subunit
B (Sdhb)
Mitochondrial
Pyruvate
Carrier 1
(Mpc1)
Mitochondrial
Pyruvate
Carrier 1
(Mpc2)
Adiponectin
(Adpn)
Citrate
synthase (Cs)
Fatty acid
binding protein
4 (aP2)
Fatty Acid
Synthase (Fas)
Adipsin (Cfd)
CCAAT
enhancerbinding protein
alpha (Cebpa)
Peroxisome
proliferatoractivated
receptor
gamma
(Pparg)

Primer 1, 5’-3’
CCACTGTCGCTTTTCGCCGC

Primer 2, 5’-3’
TGCAAACAGCTCGAAGGAGACGC

CATCATCAGCATCACCACCA

TCTTCAGGTCAATAGTCAAGCC

ATGGGAAAGACCAAAGCTGA

CCATGCAGCAGGATAGACAT

GGAGGGCAAGCAACAGTATC

GCACACAGGATGCACTCGTA

CAAGGACTTCCGGGACTATC

CATCCGCCCACTGATAATCTC

CCGACTCATGGATAAAGTGGAG CTAGTCCAGCACACACCAAT

AAAAGGGCTCAGGATGCTACTG TGGGCAGGATTAAGAGGAACA
AGAACTCATCCTGCCTCGT

CCTGCTCCTTAGGTATCAGATTG

CCCTCCTGTGCTGCAGCCTTT

GTGGCAAAGCCCACTCCCACTT

GGCATCATTGGGCACTCCTT

ACCACCAGCTGCCATGGATC

CGAGGCCGGATTCTGGG
ACAAGAACAGCAACGAGTACC

GAGTCGTCATCCGTCACTCC
TCATTGTCACTGGTCAACTCC

CGAGTGGTCTTCCATCACGG

TCACAAGAAATTACCATGGTTGAC
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2.3 Results
2.3.1

Loss of MPC1 has no effect on in vitro adipogenesis
Prior to determining the potential requirement for MPC1 expression for adipocyte

differentiation, we examined the protein expression of MPC1 and MPC2 over a seven-day
adipogenesis timecourse in 3T3-L1 cells. As shown in Figure 2.1, both MPC1 and MPC2 protein
expressions were highly induced during differentiation. The increased expression was apparent
four days after the induction of adipogenesis (Figure 2.1A and 2.1B). To assess the requirement
of MPCs on adipogenesis, we used a potent pharmacological inhibitor of MPCs, UK-5099, which
acts by binding to MPCs and modifying a thiol group to prevent the formation of the MPC1 and
MPC2 heterodimer, thus reducing pyruvate transport into the mitochondrial matrix [99,100].
Preadipocytes were induced to differentiate in the presence of UK-5099 at various doses. As shown
in Figure 2.2, a range of inhibitor doses did not inhibit adipocyte differentiation as judged by lipid
accumulation with Oil Red O staining (Figure 2.2A) or adipocyte marker gene expression (Figure
2.2B). Three adipogenic markers (adiponectin, aP2, and FAS) were examined to demonstrate
adipocyte development.
To examine the efficacy of UK-5099, respirometry experiments were performed on 3T3L1 cells to measure oxygen consumption in the presence of pyruvate with or without the addition
of the inhibitor. There were no differences in oxygen consumption observed during baseline
readings after the addition of pyruvate ± UK-5099, or oligomycin. After the addition of FCCP, the
maximal oxygen consumption rates in 3T3-L1 cells treated with the inhibitor were significantly
reduced in comparison to the control (1.167 vs. 3.411pmol/min/µg protein) (Figure 2.2C and
2.2D). Oxygen consumption rates were reduced by UK-5099 in the presence of the mitochondrial
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uncoupler, FCCP, likely due to a reduction of pyruvate substrate entry into the mitochondria. Cell
viability and cytotoxicity assays show that UK-5099-treated 3T3-L1 cells had no changes in
cytotoxicity (Figure 2.2E) or cell viability (Figure 2.2F) in comparison to DMSO, which indicates
that UK-5099 had no toxic effects on the cells.
An independent approach using siRNA-mediated knockdowns of MPC1 was also
performed to examine the role of MPCs on adipogenesis in 3T3-L1 cells. Despite substantial loss
of MPC1 protein expression (Figure 2.3A and 2.3B), there were no observed changes in
adiponectin protein expression or lipid accumulation (Figure 2.3A and 2.3C). Though Mpc1 gene
expression was significantly reduced, mRNA expression of Mpc2 and adipogenic markers, such
as Adpn, Ap2, and Pparg were not affected (Figure 2.3D). Although Cebpa gene expression
increased in the absence of MPC1, this increase did not affect adipogenesis. These data confirm
that loss of MPC1 expression does not have any significant effects on adipogenesis of 3T3-L1
cells.

Figure 2.1. MPC1 and MPC2 expression is induced during adipogenesis in 3T3-L1 cells. 3T3-L1
adipocytes were induced to differentiate using the MDI cocktail, and whole cell extracts were
harvested at the indicated time points to assess MPC1 protein expression over a timecourse of
adipocyte differentiation. A) Whole cell extracts (75 µg of protein per lane) were subjected Western
blot analysis. Adiponectin was utilized as a positive control for adipogenesis. B) Densitometry
quantification of MPC1 and MPC2 band intensities at the indicated time points. MPC1 and 2 band
intensities were normalized to ERK 1/2. (n = 3 pooled 10-cm plates per time point). Experiments
were repeated three times on independent batches of cells.
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Figure 2.2. UK-5099, a pharmacological inhibitor of MPC1, does not inhibit adipogenesis of 3T3L1 cells. A and B) 3T3-L1 preadipocytes were induced to differentiate either untreated or treated
with DMSO vehicle or indicated dose of UK-5099 at the time of induction and every 2 days during
differentiation. A) Seven days post-induction, cells were fixed and stained with Oil Red O.
Photographs are from the same experiment, and wells (n = 3 wells per treatment) were treated at
the same time. B) Seven days post-induction, RNA was isolated, purified and subjected to RTqPCR to measure gene expression of Mpc1, adipogenic markers [adiponectin (Adpn), adipocyte
lipid binding protein (Ap2), and fatty acid synthase (Fas)], and the mitochondrial marker, citrate
synthase (Cs) (n = 3 wells per treatment). Target gene expression was normalized to the reference
gene, Nono, and data are plotted as fold change over the DMSO control. C and D) Respirometry
experiments were performed to demonstrate the efficacy of the MPC1 inhibitor in mature 3T3-L1
adipocytes. After introducing 1mM pyruvate ± 10µM UK-5099, the oxygen consumption rate
(OCR) was measured using a Seahorse XF analyzer for 3 cycles prior to performing the
Mitochondrial Stress Test using 1 µM Oligomycin (Oligo), 600 nM FCCP (carbonyl cyanide 4(trifluoromethoxy) phenylhydrazone) and 5 µM Rotenone (Rot)/ Antimycin A (AA). C) Full
respiration profile showing the mean OCR normalized by the protein content ± SEM for each well
(n = 10 wells per treatment). D) Maximal respiration after the addition of 600 nM FCCP is shown
(n = 10 wells per treatment). Data shown are mean oxygen consumption rates of cells treated with
pyruvate (P) or pyruvate and UK-5099 (P+I). Panels C and D were analyzed by unpaired t-test.
**** indicates p < 0.0001 vs. pyruvate control. Experiments were repeated at least twice on
independent batches of cells. E and F) Seven days post-induction, UK-5099 treated 3T3-L1 cells
were either subjected to cytotoxicity assay (E) via ToxiLight BioAssay kit or stained with trypan
blue and counted to assess cell viability (F) at indicated doses (n = 3 wells per treatment for a
single batch of cells).
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Figure 2.3. Knockdown of MPC1 gene expression with siRNA does not inhibit adipogenesis of
3T3-L1 cells. 3T3-L1 preadipocytes were transfected with non-targeting siRNA (NT) or MPC1
siRNA upon plating and every 48 hours following induction of differentiation with MDI cocktail
until endpoint assessments protein and gene expression as well as Oil Red O staining) were
conducted on the cells at seven days post-MDI. A) Whole cell extracts were isolated and 50 µg
protein per lane were analyzed by Western blot analysis (n = 3 replicate wells per treatment).
Adiponectin was utilized as a differentiated adipocyte marker. B) MPC1 band intensities were
quantified by densitometry and normalized to ERK 1/2 for each treatment. C) The cells were fixed
and stained with Oil Red O to examine lipid accumulation. D) RNA was isolated, purified and
subjected to RT-qPCR to show gene expression of Mpc1, Mpc2, adipogenic markers [adiponectin
(Adpn), adipocyte lipid binding protein (Ap2), CCAAT enhancer-binding protein alpha (Cebpa)
and peroxisome proliferator-activated receptor gamma (Pparg)], and mitochondrial markers
[citrate synthase (Cs), oxoglutarate dehydrogenase (Ogdh) and succinate dehydrogenase (Sdhb)].
Data was analyzed by two-way ANOVA. * indicates p < 0.05, ** indicates p < 0.01, and ***
indicates p < 0.001 vs. NT control (n = 3 wells per treatment).
2.3.2

MPCs are regulated in the adipose tissue of mice during high-fat feeding
To further study MPCs, we examined MPC1 and MPC2 protein expression in several

adipose tissue depots and compared its expression with other tissues in mice. As shown in Figure
2.4, MPC1 and MPC2 were highly expressed in brown-adipose tissue (BAT), heart, liver and
kidneys in C57BL/6J mice. When directly compared, it was apparent that there are differences in
protein expression of MPC1 and MPC2 in some tissues. MPC1 had a much higher protein
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expression than MPC2 in the skeletal muscle, both the extensor digitorum longus (EDL) and the
gastrocnemius (Gastroc), and in the brain (Figure 2.4). Also, the levels of MPC1 and MPC2
expression were low in all of the white adipose tissue (WAT) depots (Figure 2.4).
To determine if MPC expression was regulated by diet-induced obesity, mice were placed
on either low-fat (LF) or high-fat (HF) diets for 12 weeks. BAT, inguinal WAT (iWAT), and
gonadal/epididymal WAT (gWAT) were harvested and analyzed in both male and female mice on
LF or HF diets. In both male and female mice, Mpc1 mRNA expression was significantly
decreased in the BAT, iWAT, and gWAT during high-fat feeding of male and female mice while
Mpc2 mRNA expression was decreased in the gWAT of males and the BAT and gWAT of females
during high-fat feeding (Figure 2.5). We also observed an expected decrease in fatty acid synthase
(Fas) gene expression during high-fat feeding [101]. Protein expression of both MPC1 and MPC2
in BAT was significantly reduced in male mice on HF diets (Figure 2.6A and 2.6B). This
significant decline in MPC1 and MPC2 levels was not observed in the female mice fed a HF diets
(Figure 2.6C and 2.6D). In iWAT, MPC1 protein expression was extremely low, near the detection
limit, and no changes in protein levels were observed as a result of HFD-feeding (data not shown).
These data indicate that MPC gene expression is downregulated in a depot and sex specific manner
by high-fat feeding.
Because female C57BL/6 mice are typically less susceptible to metabolic dysfunction
during HF diet-induced obesity than their male counterparts [102–104], we examined the
relationships between MPC1 or MPC2 protein expression and adiposity or glucose tolerance.
Protein expression of MPC1 and MPC2 for males significantly correlates with adiposity and
glucose tolerance test (GTT) AUC for male, but not female mice (Figure 2,7). For the male mice,
the linear fits of MPC1 or MPC2 versus adiposity or GTT AUC have an R2 value of greater than
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0.5 and the slopes are significantly non-zero (p < 0.01), while female mice R2 values are less than
0.4 and none of the slopes are significantly non-zero. These data show that decreased levels MPC
proteins in male mice are associated with increased adiposity and decreased glucose tolerance.

Figure 2.4. MPC1 and MPC2 proteins are highly expressed in brown adipose tissue, liver, and
heart. Select tissues were harvested from a 27-week old C57BL/6J mouse to assess the tissue
distribution of MPC1 and MPC2 proteins. A) Tissue samples were homogenized and 100 µg of
total protein per lane were analyzed by Western blotting. B) MPC1 and MPC2 band intensities
were quantified by densitometry and normalized to respective ERK 1/2 intensities for each tissue
depot. gWAT, gonadal WAT; rpWAT, retroperitoneal WAT; iWAT, inguinal WAT; mWAT,
mesenteric WAT; BAT, brown AT; EDL, extensor digitorum longus; gastroc, gastrocnemius.
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Figure 2.5. Steady state mRNA expression of MPC1 is substantially decreased in adipose tissue
after high-fat feeding in male and female C57BL/6J mice. Six-week old C57BL/6J mice were fed
either a high-fat (HF) or low-fat (LF) diet for 12 weeks ad libitum before euthanizing and collecting
tissue. BAT, iWAT, and gWAT samples were homogenized and RNA was isolated and purified
from each tissue depot for male (A) and female (B) mice. Each sample was subjected to RT-qPCR
to show gene expression of Mpc1, Mpc2, adipogenic markers (Adpn, Ap2, and Fas), adipokine
(Adipsin), and mitochondrial marker (Cs). Data was analyzed by unpaired t-tests. * indicates p <
0.05, ** indicates p < 0.01, *** indicates p < 0.001, and **** indicates p < 0.0001 vs. LF diet (n
= 6 per condition). Each sample was run in duplicate. Target gene expression was normalized to
the reference gene, Cyclophilin A, and data are plotted as fold change over the LF control.
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Figure 2.6. MPC1 and MPC2 expression is significantly decreased in the brown adipose tissue of
male, but not female mice following high-fat feeding. Six-week old male and female C57BL/6J
mice were fed either a high-fat (HF) or low-fat (LF) diet for 12 weeks ad libitum before euthanizing
and collecting BAT. Tissue samples were homogenized, and 30 µg of total protein per lane were
subjected to Western blot analysis (n = 6 per condition) for males (A) and females (C). MPC1 and
MPC2 band intensities were quantified by densitometry and normalized to respective STAT3
intensities for each sample; males (B) and females (D). Data was analyzed by two-way ANOVA.
** indicates p < 0.01 vs. LF diet.
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Figure 2.7. Decreased MPC1 and MPC2 protein expression in BAT during DIO correlates with
increased adiposity and decreased metabolic health in male, but not female, mice. A and B) MPC
protein expression from the immunoblot quantification in Figure 6B and 6D was correlated with
percent fat mass (adiposity) for male and female mice on LFD and HFD. Protein extracts were
collected, and adiposity measured at 19 weeks of age (12 weeks on diet). C and D) MPC protein
expression values for male and female mice were also plotted against area under the curve (AUC)
of glucose tolerance tests (GTTs) performed on LFD and HFD-fed mice at 17 weeks of age (10
weeks on diet) for male and female mice. Linear regression analyses were performed and are
shown for data in A-D. R2 values indicate goodness of the linear fit for each data set, and whether
the slope is significantly differently from zero is denoted by p value or ns (not significant).

2.4 Discussion
Our novel data demonstrate the dispensability of MPC1 during adipogenesis in vitro as
well as showing the expression and modulation of MPCs in brown adipose tissue in vivo during
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diet-induced obesity (DIO). The observed increase in protein expressions of both MPC1 and
MPC2 during adipocyte differentiation of 3T3-L1 cells (Figure 2.1) has not been previously
reported in 3T3-L1 cells, but MPC1 and MPC2 expression is increased upon differentiation of
LGR5+ intestinal stem cells (ISCs) [105]. The increase in MPC1 and 2 expressions in adipocytes
is likely due to increased mitochondrial density and gene expression that occurs to generate energy
needed to accommodate the enhanced metabolic requirements during adipogenesis [91,94,95].
Because of enhanced protein expression of MPCs during differentiation, we hypothesized that
MPCs were necessary for the differentiation of 3T3-L1 cells.
Contrary to our premise, two independent approaches using both pharmacological
inhibition with UK-5099 (Figure 2.2) and siRNA-mediated knockdowns (Figure 2.3) of MPCs did
not affect adipocyte development. Even at doses as low as 50nM, UK-5099 has been able to inhibit
formation of the MPC1 and 2 heterodimer, thus inhibiting pyruvate transport via this complex
[87,99]. In BAT progenitor cells, the addition of UK-5099 inhibited 13C-glucose incorporation into
acetyl CoA [99] suggesting that the pyruvate produced from glycolysis of

13

C-glucose was not

utilized for acetyl CoA production due to impaired pyruvate uptake by the MPC heterodimer via
UK-5099 inhibition. Liver-specific loss of MPC2 in C57BL/6J mice resulted in compromised, but
not eliminated, pyruvate metabolism and suggested that mechanisms such as pyruvate-alanine
cycling were activated to compensate for the loss of the MPC complex functionality [106]. A
robust decline (~80%) in MPC1 expression via siRNA knockdowns also had no effect on adipocyte
development (Figure 2.3). Our data further supports the current literature. Our observations
suggest that although pyruvate is the primary substrate for energy production in the mitochondria,
other substrates, such as alanine, glutamine [85,106,107], or branched chain amino acids [108],
might bypass the MPC1/2 complex and enter into the mitochondrial matrix to compensate for the
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lack of pyruvate transport under conditions where MPC1 or MPC2 is not present or functional. A
clear limitation of our adipogenesis studies is that they are solely in vitro observations. Although
our findings show that the loss of MPC expression in vitro has no effect on adipocyte development,
other in vivo studies have found that C57BL/6 mice with an adipocyte-specific loss of MPC1 had
increased fatty acid oxidation, increased levels of triglycerides in circulation, deficiencies in
storage of TGs, and mitochondrial damage. It was also observed that heterozygous MPC1
knockdown mice had decreased body weight, activity, fat accumulation, and low body shell
temperatures during cold exposure [90,109].
An analysis of several mouse tissue samples revealed that MPCs are highly expressed in
BAT, heart, lung, and skeletal muscle (Figure 2.4). This is an expected finding, as each of these
are mitochondria-rich tissues. However, it has not been reported that MPC1 and MPC2 are more
highly enriched in BAT than other mitochondria-rich tissues (Figure 2.4). Because MPCs are
highly enriched in BAT depots, but not in WAT depots, we assessed whether MPCs were regulated
in AT depots during diet-induced obesity (DIO). Although MPC1 was downregulated in BAT and
WAT during high-fat feeding at the mRNA level (Figure 2.5), MPC1 protein expression was
barely detectable and not obviously changed in the WAT of either male or female mice during
high-fat feeding (data not shown). The differences in gene and protein expression could be due to
a variety of factors including translational rates, protein degradation rates, or a combination of both
factors [110]. However, it is a novel finding that MPC gene and protein expressions are
downregulated in BAT of male, but not female, mice during DIO (Figures 2.5 and 2.6). It has been
reported that reductions in diet-induced thermogenesis contribute to weight gain after consumption
of high fat meals [111]. In addition, glucose oxidation rates are significantly decreased in subjects
after consuming high-fat meals [111]. This literature suggests that the decreased MPC expression
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correlates with decreased diet-induced thermogenesis that occurs with prolonged high-fat feeding.
Also, the sex-specific regulation of MPCs (Figure 2.6) is likely attributed to sex-specific metabolic
responses to high fat feeding in C57BL/6J mice [103]. Unlike male mice, previous studies have
shown that female mice are more metabolically healthy, have reduced inflammation, and are more
insulin sensitive despite having obesity while on HFD [102–104]. Accordingly, in our study the
female mice on HFD had 27% higher adiposity than the male HFD-fed mice, but improved glucose
metabolism during an intraperitoneal glucose tolerance test. Data in Figure 2.7 demonstrate that
decreased MPC protein levels correlate with increased adiposity and glucose intolerance in male,
but not female, mice. We speculate that the variations in expression of MPC1 and MPC2 between
male and female mice are due to differences in metabolic health and that MPCs are specifically
regulated in brown, but not white, AT depots in conditions of metabolic dysfunction.
In summary, our findings demonstrate that (1) the expression of MPCs is induced during
adipocyte development, but not required for adipogenesis, (2) a loss of MPC expression or activity
during adipogenesis likely promotes the activation of alternative mechanisms to compensate for
the loss of pyruvate transport, and (3) MPC expression is highly enriched in BAT but decreased
as a result of high-fat feeding or diet-induced obesity. Future studies will be needed to determine
which substrates can be utilized to compensate for the loss or dysfunction of MPCs. In addition, it
is necessary to determine whether adipogenesis in BAT is dependent on MPCs. Also, future studies
will be necessary to determine whether the observed in vitro effects on adipogenesis are similar to
in vivo models.
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CHAPTER 3. KAT8, LYSINE ACETYLTRANSFERASE 8, IS REQUIRED
FOR ADIPOCYTE DIFFERENTIATION IN VITRO
3.1 Introduction
Histone acetyltransferases (HATs) are enzymes that transfer acetyl groups from acetyl CoA
to specific lysine residues on target proteins that are often histones. Histone acetylation modulates
chromatin structure and gene expression and is primarily controlled by HATs and reversed by
histone deacetylases (HDACs). HATs acetylate other proteins besides histones and are now more
commonly referred to as lysine acetyltransferases, or KATs. Of the family of KATs, KAT8 has
been reported to play a role in many cellular functions. KAT8 was initially described as malesabsent-on-the-first (MOF) in Drosophila melanogaster, because it is a male-specific protein that
exhibits lethality when mutated in males [62]. In Drosophila, KAT8 contributes to two regulatory
complexes, male-specific lethal (MSL) and non-specific lethal (NSL), that both contribute to
transcriptional activation [63] [64]. KAT8 is present in mammalian species in which the MSL
complex is conserved [63]. KAT8, also known as MYST1, is a member of the MYST (MOZ,
YBF2/SAS2, and TIP 60 protein 1) family of histone acetyltransferases that are characterized by
their roles in post-translational modifications of histone and chromatin remodeling in eukaryotes
[65] [66]. KAT8 and other MYST proteins have a conserved MYST domain that consists of an
acetyl CoA-binding motif, as well as a CCHC-type zinc finger that confers substrate recognition
[66]. KAT8 also has a N-terminal chromodomain (CHD) which plays a role in RNA binding
[67,68], a HAT domain, and a chromobarrel domain (CBD) at the C-terminal which modulates
HAT activity [62,63]. KAT8 has a variety of substrates and can modulate many biological
processes, including cell cycle regulation, embryonic development and tumorigenesis [69–76,79].
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The most thoroughly characterized target of KAT8 in mammalian cells is Histone 4 Lysine
16 (H4K16), where it participates in protein complexes that are involved in transcriptional
regulation [69]. KAT8 can also acetylate H4K5 and H4K8 [69]. Disruption of KAT8 expression
and/or function can result in irregularities in cell cycle, cell proliferation, gene transcription, DNA
damage repair, and early embryonic development, or promotion of tumorigenesis in a variety of
cell types [69,70,79]. Histones are well-known targets for KAT8 activity, but KAT8 acetylates
other proteins.

Acetylation of LSD1 (lysine-specific histone demethylase 1) by KAT8 is

associated with reduced tumorigenesis [71], while KAT8-mediated acetylation of the tumor
suppressor p53 promotes cellular apoptosis in response to DNA damage [72–74]. KAT8 can also
acetylate DBC1 (deleted in breast cancer 1) and reduce its binding affinity for the histone
deacetylase, sirtuin 1 (SIRT1) to increase SIRT1 activity [75].
The incidence of obesity and related metabolic diseases, such as Type 2 Diabetes Mellitus,
continues to rise around the world and represents one of the greatest public health challenges of
our time. Obesity is characterized by the expansion of adipose tissue via hyperplasia and
hypertrophy of adipocytes. Adipose tissue plays a key role in metabolic health, and disruption of
adipocyte development or fat cell functions is associated with poor metabolic outcomes [112–114].
In addition to the roles of KAT8 described above, there is evidence that KAT8 can be influenced
by or interact with proteins important in adipocyte development and function. It was reported that
KAT8 expression is modulated by signal transducer and activator of transcription 5B (STAT5B)
during adipogenesis [83]. Also, in HEK293T cells KAT8 has been shown to acetylate fatty acid
synthase (FASN) and promote its degradation via ubiquitylation [76]. FASN is the principal
enzyme of de novo lipogenesis and is critical for adipocyte development and function. Most
importantly, a genome-wide associated study (GWAS) meta-analysis identified KAT8 as 1 of 97
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body mass index (BMI)-associated loci that account for variations in BMI [84]. These studies
prompted us to examine the role of KAT8 in adipogenesis.
Our novel studies reveal that KAT8 is expressed in adipocytes and plays a role in adipocyte
development in vitro. The use of small interfering RNA (siRNA) to knock down KAT8 expression
in preadipocytes and adipocytes revealed that KAT8 expression is required for the adipogenesis
of 3T3-L1 cells but does not affect lipid accumulation or adipocyte marker levels in mature
adipocytes. In contrast with what has been observed in other cell types [76], loss of KAT8
expression in adipocytes did not affect FASN levels.
3.2 Materials and Methods
Cell culture: Murine 3T3-L1 preadipocytes were grown in Dulbecco’s Modified Eagle’s Media
(DMEM) (Sigma-Aldrich, St. Louis, MO) with 10% bovine calf serum. Two days after confluence,
preadipocytes were induced to differentiate using a standard protocol and induction cocktail
composed of 3-isobutyl-methylxanthine, dexamethasone, insulin (MDI), and 10% characterized
fetal bovine serum (FBS) in DMEM. HyClone calf and fetal bovine sera were purchased from
Thermo Scientific (Waltham, MA) or GE Healthcare Life Sciences (Marlborough, MA). The
medium was changed every 48 -72 hours during growth and differentiation.
Whole-cell extract preparation: Cell monolayers were rinsed once with phosphate-buffered
saline (PBS) and then scraped into non-denaturing immunoprecipitation (IP) buffer containing
10mM Tris (pH 7.4), 150mM NaCl, 1mM EGTA, 1mM EDTA, 1% Triton X-100, 0.5% IGEPAL
CA-630, protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 1 μM pepstatin, 50 trypsin
inhibitory milliunits of aprotinin, 10 μM leupeptin, 1 mM 1,10-phenanthroline), and phosphatase
inhibitors (0.2mM sodium vanadate and 100 μM sodium fluoride). The whole-cell extracts were
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stored at -80°C before being thawed and passed through a 20-gauge needle seven times, then
clarified via centrifugation at 13,000 x g for 10 min at 4°C.
Small interfering RNA (siRNA)-mediated knockdown during differentiation:

3T3-L1

preadipocytes, approximately 70% confluent in 10-cm plates, were trypsinized and re-plated in 6well plates at a density of 5.8 x 105 cells/cm2 in antibiotic-free 10% bovine calf serum/DMEM.
Using the protocol from Dharmacon, preadipocytes were transfected with 33 nM siRNA
(Dharmacon, Lafayette, CO; Non-targeting siRNA Cat #: D-001810-10-50, siRNA targeting
KAT8 Cat #: L-048962-01-0010) and the DharmaFECT Duo transfection reagent (Dharmacon,
Lafayette, CO, Cat #: T-2010-03) in OptiMEM reduced serum medium (Thermo Fisher, Waltham,
MA; Cat #: 31985088). Non-targeting siRNA was used as negative control. Cells were treated
with the siRNA cocktail during initial plating and grown to confluence. Two days after confluence,
cells were induced to differentiate with the MDI-induction cocktail, as described above, and
transfected again with the siRNA cocktail. After 48 hours, the cells were treated with ¼ normal
dose of insulin and transfected once again with the siRNA cocktail. Cells were fed every 48 hours
with antibiotic-free media throughout the entire knockdown process. Seven days after the
induction of differentiation, the cell monolayers were harvested for protein in IP buffer, and for
RNA in buffer provided in the RNeasy mini kit (Qiagen, Hilden, Germany) to assess knockdown
efficiency. Three biological and technical replicates were analyzed for each data set.
Small interfering RNA (siRNA)-mediated knockdown in mature adipocytes: Fully
differentiated 3T3-L1 adipocytes were trypsinized and re-plated in 6-well plates at a density of 5.8
x 105 cells/cm2 in antibiotic-free 10% fetal bovine serum/DMEM. Using the protocol from
Dharmacon, preadipocytes were transfected with 50 nM siRNA (Dharmacon, Lafayette, CO; Nontargeting siRNA Cat #: D-001810-10-50, siRNA targeting KAT8 Cat #: L-048962-01-0010) and
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the DharmaFECT Duo transfection reagent (Dharmacon, Lafayette, CO, Cat #: T-2010-03) in
OptiMEM reduced serum medium (Thermo Fisher, Waltham, MA; Cat #: 31985088). Nontargeting siRNA was used as negative control. Cells were treated with the siRNA cocktail during
initial plating. The cell monolayers were harvested 48 hours later for protein in IP buffer, and for
RNA in buffer provided in the RNeasy mini kit (Qiagen, Hilden, Germany) to assess knockdown
efficiency. Three biological and technical replicates were analyzed for each data set.
Gel electrophoresis and immunoblotting: Protein content of cell extracts was quantified via
BCA assay. Samples were separated on 7.5%, 12%, or 15% sodium dodecyl sulfate (SDS)
polyacrylamide (PA) gels (acrylamide; National Diagnostics, Atlanta, GA; Cat #: EC-890) and
transferred to nitrocellulose membranes (BioRad, Hercules, CA; Cat #: 162-0115) in 25 mM Tris,
192 mM glycine, and 20% methanol. After the transfer, membrane strips were blocked in 4% nonfat milk for 1 hour at room temperature and washed with tris-buffered saline + 0.1% Tween-20
(TBS-T) before incubating with primary antibodies in 1% BSA-TBS-T overnight at 4°C. Strips
were washed with TBS-T and then incubated with either anti-mouse or anti-rabbit horseradish
peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch, West Grove, PA) for 1h.
Strips were washed with TBS-T and visualized with enhanced chemiluminescence (Pierce/Thermo
Scientific, Waltham, MA).
Antibodies: Transferrin (ab82411; rabbit polyclonal) and the MitoProfile Total OXPHOS Rodent
WB antibody mixture (ab110413; rabbit polyclonal) antibodies were purchased from Abcam
(Cambridge, MA). Anti-PPARg (E-8; sc-7273; mouse monoclonal) antibody was purchased from
Santa Cruz Biotechnology (Dallas, TX). Anti-adiponectin (PA1-054; rabbit polyclonal) antibody
was purchased from Thermo Scientific (Waltham, MA). Anti-DBC1 (5693S; rabbit polyclonal),
anti-FASN (3180S; C20G5; rabbit monoclonal), anti-ERK1/2 (4695S; 137F5; rabbit monoclonal),
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and anti-MYST1 (4682S; D5T3R; rabbit monoclonal) antibodies were purchased from Cell
Signaling Technology (Danvers, MA).
RNA analysis: Total RNA from adipocyte monolayers was purified using the RNeasy mini kit
(Qiagen, Hilden, Germany). Purified RNA was used for reverse transcription (RT) to generate
cDNA according to the Applied Biosystems protocol (Applied Biosystems, Foster City, CA; Cat
#: 4368813). cDNA was quantified using the real-time quantitative PCR (qPCR) method in a total
volume of 10 µL (2 µL cDNA and 8 µL reaction master mix) using an Applied Biosystems
7900HT System with SDS 2.4 software, Takara SYBR premix (Takara Bio USA Inc., Madison,
WI, USA), and primers from IDT (Integrated DNA Technologies, Skokie, IL, USA). Thermal
cycling conditions were as follows 2 min at 50 °C; 10 min at 95 °C; 40 cycles of 15 s at 95 °C and
1 min at 600C; final dissociation stage of 15 s at 95 °C, 15 s at 60 °C, and 15 s at 95 °C. Non-POU
domain containing octamer binding protein (NoNo) was used as a reference gene. The following
mouse genes were examined by RT-qPCR: Adiponectin (Adpn), Fatty Acid Binding Protein 4
(aP2), Fatty Acid Synthase (Fasn), Glucose Transporter 4 (Glut4), and Lysine Acetyltransferase
8 (KAT8). Primer sequences are shown in Table 1.
Lipid Staining: Seven days after the induction of differentiation, cells were fixed and stained with
Oil Red O (ORO; Sigma-Aldrich, St. Louis, MO, USA) as described previously [19].
Statistical analysis: Statistical analyses were performed using GraphPad Prism software (version
8; La Jolla, CA, USA). Differences between groups were calculated using two-way ANOVA.
Results are shown as mean ± standard error of the mean (SEM). Results were considered
statistically significant when p < 0.05.
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Table 3.1. qPCR Primer Sequences
Gene Primer 1, 5’-3’

Primer 2, 5’-3’

Non-POU CATCATCAGCATCACCACCA
domain
containing
octamer binding
protein (Nono)
Adiponectin TGTCTGTACGATTGTCAGTGG
(Adpn)
Fatty acid CCCTCCTGTGCTGCAGCCTTTC
binding protein 4
(aP2)
Fatty Acid GGCATCATTGGGCACTCCTT
Synthase (Fasn)
Glucose GAGAATACAGCTAGGACCAGTG
Transporter 4
(Glut4)

TCTTCAGGTCAATAGTCAAGCC

GCAGGATTAAGAGGAACAGGAG
GTGGCAAAGCCCACTCCCACTT

ACCAACAGCTGCCATGGATC
TCTTATTGCAGCGCCTGAG

Lysine CGAGTACTGCCTCAAATACATGA GCCATCCACTTCATACACAGA
Acetyltransferase
8 (Kat8)

3.3 Results
We examined the expression of KAT8 mRNA and protein over a time course of adipocyte
development using the 3T3-L1 model system. As shown in Figure 3.1A, KAT8 protein levels were
highest in preadipocytes (time 0) but did not change over the period of adipocyte development. As
expected, adiponectin levels increased during adipogenesis, and ERK levels were unchanged.
Similarly, there we no effects on Kat8 gene expression during adipogenesis despite the timedependent increase in aP2, adiponectin, and fatty acid synthase mRNA levels (Figure 3.1B). In
mature adipocytes, subcellular fractionation demonstrated that although KAT8 primarily localizes
in the nucleus, it is also present in the cytosol, but not in the mitochondria (Figure 3.2). DBC1
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was utilized as a positive control for nuclear protein and ERK1/2 was utilized as a positive control
for cytosolic protein. COX1 was used as positive control for mitochondrial protein.
To assess the requirement of KAT8 for adipogenesis, we performed siRNA-mediated
knockdowns of KAT8 in 3T3-L1 preadipocytes prior to adipogenesis and assessed adipocyte
differentiation 7 days post-induction. Effective knockdown of the Kat8 gene was confirmed by
qPCR (Figure 3.3A). The induction of three adipogenic mRNAs, adiponectin (Adpn), aP2/FABP4,
and fatty acid synthase were also inhibited with KAT8 knockdown. The loss of KAT8 protein was
confirmed by western blot analysis and was associated with reduced expression of adiponectin and
PPARg, the primary regulator of adipogenesis (Figure 3.3B). ERK levels were examined as a
loading control. Loss of KAT8 during adipogenesis was also associated with an inhibition of lipid
accumulation as judged by Oil Red O staining of neutral lipids (Figure 3.3C). Although FASN
mRNA expression is markedly decreased, non-targeting siRNA did not attenuate adipocyte marker
protein expression or lipid accumulations (Figures 3.3A-C).
We also performed siRNA-mediated knockdowns of KAT8 in mature adipocytes to
evaluate potential effects on lipid accumulation and expression of adipogenic markers. Unlike the
loss of KAT8 during differentiation of preadipocytes, a significant loss of Kat8 expression in
mature 3T3-L1 adipocytes was not associated with decreased expression of various adipogenic
marker mRNAs, including adiponectin, aP2, Glut4, and Fasn (Figure 3.4A). Although KAT8
protein expression was significantly reduced, there were no differences in protein expression of
adiponectin or FASN in the KAT8 siRNA-transfected condition as compared to non-targeting
siRNA in adipocytes (Figure 3.4B). Of note, the siRNA treatments were associated with decreased
expression of adiponectin and FASN and with an increase in transferrin levels, but these effects

40

were not due to the loss of KAT8. In addition, loss of KAT8 in mature adipocytes had no effect
on neutral lipid accumulation, as judged by Oil-Red O staining (Figure 3.4C).

Figure 3.1. KAT8 expression over a time course adipogenesis in 3T3-L1 cells. 3T3‐L1
preadipocytes were induced to differentiate using the 3‐isobutyl‐methylxanthine, dexamethasone,
insulin (MDI) cocktail, and cells were harvested at the indicated time points to assess KAT8 gene
and protein expression over a time course of adipocyte differentiation. (A) Whole‐cell extracts (50
µg of protein per lane) were subjected to Western blot analysis. Adiponectin was utilized as a
positive control for adipogenesis. (B) RNA was isolated, purified, and subjected to RT‐qPCR to
measure gene expression of Kat8, adipogenic markers (adiponectin [Adpn], fatty acid synthase
[Fasn], and fatty acid binding protein [aP2] (n = 3 wells per treatment). Marker gene expression
was normalized to the reference gene, Nono.
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Figure 3.2. KAT8 is expressed in the nucleus and cytosol of 3T3-L1 cells, but not in mitochondria.
Monolayers of fully differentiated 3T3-L1 cells were collected and subjected to subcellular
fractionation that was optimized to separate cytosolic (cyto), nuclear (nuc), and mitochondrial
(mito) fractions. Fractionated samples (40 µg of protein per lane) were subjected to Western blot
analysis. This experiment was independently performed on three different batches of adipocytes
with identical results.
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Figure 3.3. KAT8 expression is required for adipogenesis of 3T3‐L1 cells. 3T3‐L1 preadipocytes
were transfected with non-targeting (NT) siRNA or KAT8 siRNA upon plating and every 48 hours
following induction of differentiation with MDI cocktail until end point assessments. Protein and
gene expression assessments as well as Oil Red O staining were conducted on the cells at 7 days
post MDI. (A) RNA was isolated, purified, and subjected to RT‐qPCR to assess gene expression
of Kat8 and adipogenic markers (adiponectin [Adpn], fatty acid synthase [Fasn], and fatty acid
binding protein 4 [aP2]). Data were analyzed by two‐way ANOVA. *P < 0.05 and ****P < 0.0001
vs. NT control (n= 3 wells per treatment). (B) Whole‐cell extracts were isolated, and 40 µg
of protein per lane was analyzed by Western blot analysis (n= 2-3 pooled
replicates/well/treatment). (C) Cells were fixed and stained with Oil Red O to examine lipid
accumulation. Each panel is representative of an experiment performed on at least three
independent batches of cells.
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Figure 3.4. The loss of Kat8 in mature 3T3‐L1 adipocytes does not affect adipocyte marker
expression or neutral lipid content. Fully differentiated 3T3‐L1 adipocytes were transfected with
non-targeting (NT) siRNA or KAT8 siRNA. Cells were harvested for protein and gene expression
assessments or fixed for Oil Red O staining 48 hours post-transfection. (A) RNA was isolated,
purified, and subjected to RT‐qPCR to examine gene expression of Kat8 and adipogenic markers
(adiponectin [Adpn], fatty acid binding protein 4 [aP2], glucose transporter 4 [Glut4], and fatty
acid synthase [Fasn]). Data were analyzed by two‐way ANOVA. *P < 0.05 and ****P < 0.0001
vs. NT control (n= 3 wells per treatment). (B) Whole‐cell extracts and media were isolated and
150 µg of protein per lane was analyzed by Western blot analysis (n= 3 replicates/treatment). (C)
Cells were fixed and stained with Oil Red O to examine neutral lipid accumulation. Each panel is
representative of at least three experiments performed on independent batches of adipocytes.
3.4 Discussion
KAT8 is expressed in preadipocyte and adipocytes, but neither KAT8 mRNA nor protein
levels are highly regulated during adipogenesis (Figure 3.1). Another study has indicated that
KAT8 expression is increased during adipocyte differentiation in the 3T3-L1 model system. [83].
However, our gene and protein expression data from experiments repeated several times do not
support this observation. Of note, KAT8 expression is regulated during differentiation of other cell
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types, including oocytes and glioblastomas [115,116]. In addition, KAT8 has also been shown to
be required in the maintenance of embryonic stem cell self-renewal and pluripotency [117], and
siRNA-mediated loss of KAT8 impairs formation and proliferation of porcine blastocysts [118].
In vitro, adipogenesis is dependent on a process referred to as mitotic clonal expansion, where
cells undergo one to two rounds of proliferation prior to differentiation and a permanent exit from
the cell cycle. It is possible that KAT8 is required for adipogenesis in vitro, due to its effects on
regulating proliferation. Future studies will be needed to determine if KAT8 is a crucial modulator
of adipogenesis in vivo.
In adipocytes, we observed that KAT8 is present in the cytosol, but KAT8 protein levels
are enriched in the adipocyte nucleus (Figure 3.2). KAT8 subcellular localization varies between
cell types. In HeLa cells, KAT8 is found in the mitochondria where it binds mitochondrial DNA
and regulates mitochondrial gene expression associated with respiration [119]. Notably, in HeLa
cells lacking KAT8, a mitochondrial wild-type KAT8, but not a catalytic mutant, can restore
respiratory and transcriptional defects induced by loss of KAT8 [119]. Further support for a role
of KAT8 in mitochondrial respiration comes from studies in failing human and murine hearts,
where KAT8 expression is decreased [120]. Future studies will be needed to determine how the
nuclear and mitochondrial pools of KAT8 contribute to regulation of transcription and energy
metabolism in complex tissues, including adipose tissue.
Use of siRNA knockdowns revealed that KAT8 expression is required for adipogenesis in
the 3T3-L1 model system (Figure 3.3). The only other study of KAT8 in adipocytes indicated that
KAT8 was increased during adipogenesis, and that the KAT8 promoter was bound by STAT5B
[83]. In that study, loss of KAT8 led to increased expression of adipocyte marker genes and the
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study’s authors concluded that KAT8 and STAT5B were negative regulators of adipogenesis.
However, STAT5 proteins are well-known positive regulators of adipocyte development in vitro
and in vivo [121,122]. Hence, these observations are in conflict with the data from our rigorous
studies and with what is known about STAT5’s role in adipogenesis. To our knowledge, there are
no published studies on loss of KAT8 in adipocytes in vitro or in vivo. Our data reveal that loss of
KAT8 in mature adipocytes is not accompanied by decreased expression of adipocyte markers
such as adiponectin, fatty acid synthase, or GLUT4 (Figure 3.4A and B). Moreover, a 48-hour
knockdown of KAT8 produced no changes in neutral lipid accumulation in adipocytes (Figure
3.4C). These data suggest that KAT8 has different functions in preadipocytes and adipocytes,
which is not a surprise given the diverse functions of KAT8 in a variety of cell types.
Since KAT8 has cell-specific functions, it will be important to determine the function of
this acetyltransferase during adipogenesis as well as in mature adipocytes. Our observations on
KAT8 are novel and, except for the study cited above, there are no other data on KAT8 in
adipocytes. However, a GWAS study has identified KAT8 in a locus associated with variability in
body mass index [84]. Of other possible relevance is a study in HEK293 cells showing that KAT8
can regulate fatty acid synthase (FASN) expression via acetylation [76]. Since FASN is essential
for lipogenesis, we predicted that FASN might be a substrate of KAT8 in mature adipocytes.
However, loss of KAT8 in mature fat cells did not affect FASN expression (Figure 3.4B) or halflife (data not shown). Overall, our data demonstrate that KAT8 is required for in vitro
adipogenesis, but not for expression of adipocyte markers in mature fat cells. These data suggest
that KAT8 likely has different functions in preadipocytes and adipocytes. In adipocytes, KAT8 is
largely present in the nucleus, suggesting it is likely involved in transcriptional regulation. Our
current efforts are focused on identifying KAT8 substrates in mature adipocytes. Given its role in
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adipogenesis and its expression in adipocyte nuclei, it is likely that KAT8 contributes to fat cell
function.
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CHAPTER 4. KAT8, LYSINE ACETYLTRANSFERASE 8, IS EXPRESSED
AND NUTRITIONALLY REGULATED IN ADIPOSE TISSUE
4.1 Introduction
Although many epigenetic modifiers have been characterized, much remains unknown
about their roles in vivo. KATs are a group of epigenetic modifiers characterized by their ability
to reversibly acetylate histones and many other proteins. Approximately 15 KATs have been
identified and categorized into 3 families: the MYST family (for Moz, Ybf2/Sas3, Sas2, and
Tip60), the general control nonderepressible 5 (GCN5) family, and the CREB-binding protein
(CBP) family [123–125]. Within the MYST family there are 5 KATs (KAT5, KAT6A, KAT6B,
KAT7, and KAT8) that have been characterized and show target specific acetylation of histones.
KAT6A and KAT6B acetylate histone 3 lysine 23 (H3K23) while KAT7 acetylates at H3K14
[125]. Unlike other members of the MYST family, KAT8 acetylates histone 4 at lysine 16 (H4K16)
suggesting differing functionality than other MYST members [125].
As previously stated, the exponential increase in the global incidence of obesity and
metabolic diseases has serious health-related and economic repercussions around the world.
Adipose tissue is known to play a critical role in metabolic health and is the subject of intense
study as a potential therapeutic target for metabolic dysfunction. KAT8 plays a role in cell cycle
progression, cell proliferation, DNA damage repair, gene transcription, promotion of autophagy,
tumorigenesis, and early embryonic development [69,70,77–79]. However, there is only scant
evidence for a role of KAT8 in adipocytes, and no mechanistic studies have assessed KAT8 in
adipose tissue.
In order to further evaluate the potential functions of KAT8 in fat, we examined KAT8’s
expression and regulation in adipose tissue. Our novel studies reveal that KAT8 is highly expressed
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in various white adipose tissue (WAT) depots. In addition, tissue digestion and fractionation
reveals that KAT8 expression is enriched in adipocytes, but also expressed in non-adipocyte cells
of adipose tissue. We have also demonstrated that KAT8 is nutritionally regulated by DIO and
fasting/refeeding. Although the mechanisms are unknown, these findings advance the field and
lead to a deeper understanding of KAT8 functionality in adipose tissue.
4.2 Materials and Methods
Animals and Diets- Four-week-old male and female C57BL/6J mice were purchased from
Jackson Laboratories (Stock #000664; Bar Harbor, ME). Animals were housed in a temperature
(22 ± 2°C)- and humidity-controlled (45–55%) room under a 12-h light/dark cycle. At six weeks
of age, mice were placed on respective diets with ad libitum access to food and water. For twelve
weeks, mice had access to either low-fat diet (LFD) containing 20% kcal protein, 70% kcal
carbohydrate, and 10% kcal fat (D12450J; Research Diets, Inc. New Brunswick, NJ) or high-fat
diet (HFD) containing 20% kcal protein, 20% kcal carbohydrate, and 60% kcal fat (D12492;
Research Diets, Inc. New Brunswick, NJ). Body weights were obtained biweekly. Mice were
fasted for four hours prior to sacrifice. For fasting and refeeding studies, thirteen-week-old female
mice were either fasted for eighteen hours or fasted for fourteen hours then allowed ad
libitum access to food and water for four hours before sacrifice. All animal studies were performed
with approval from the Pennington Biomedical Research Center Institutional Animal Care and
Use Committee.
Cell culture- Murine 3T3-L1 preadipocytes were grown in Dulbecco’s Modified Eagle’s Media
(DMEM) (Sigma-Aldrich, St. Louis, MO) with 10% bovine calf serum. Two days after confluence,
the preadipocytes were induced to differentiate using a standard protocol and induction cocktail
composed of 3-isobutyl-methylxanthine, dexamethasone, insulin (MDI), and 10% characterized
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fetal bovine serum (FBS) in DMEM. HyClone calf and fetal bovine serum were purchased from
Thermo Scientific (Waltham, MA) or GE Healthcare Life Sciences (Marlborough, MA). The
medium was changed every 48 – 72 hours during growth and differentiation. Cells were treated
with 5 µM cycloheximide (CHX) for indicated times before harvesting cell monolayers.
Whole-cell extract preparation- Cell monolayers were rinsed once with phosphate-buffered
saline (PBS) and then scraped into non-denaturing immunoprecipitation (IP) buffer. These extracts
were stored at -80°C before being thawed, passed through a 20-gauge needle five times, and
clarified via centrifugation at 13,000 x g for 10 min at 4°C.
Small interfering RNA (siRNA)-mediated knockdown during differentiation:

3T3-L1

preadipocytes, approximately 70% confluent in 10-cm plates, were trypsinized and re-plated in 6well plates at a density of 5.8 x 105 cells/cm2 in antibiotic-free 10% bovine calf serum/DMEM.
Using the protocol from Dharmacon, preadipocytes were transfected with 33 nM siRNA
(Dharmacon, Lafayette, CO; Non-targeting siRNA Cat #: D-001810-10-50, siRNA targeting
KAT8 Cat #: L-048962-01-0010) and the DharmaFECT Duo transfection reagent (Dharmacon,
Lafayette, CO, Cat #: T-2010-03) in OptiMEM reduced-serum medium (Thermo Fisher, Waltham,
MA; Cat #: 31985088). Non-targeting siRNA was used as negative control. Cells were treated
with the siRNA cocktail during initial plating and grown to confluence. Two days after confluence,
cells were induced to differentiate with the MDI-induction cocktail, as described above, and
transfected again with the siRNA cocktail. After 48 hours, the cells were treated with ¼ normal
dose of insulin and transfected once again with the siRNA cocktail. Cells were fed every 48 hours
with antibiotic-free media throughout the entire knockdown process. Seven days after the
induction of differentiation, the cell monolayers were harvested for protein in IP buffer, and for
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RNA in buffer provided in the RNeasy mini kit (Qiagen, Hilden, Germany) to assess knockdown
efficiency.
Gel electrophoresis and immunoblotting- Protein content of cell extracts was quantified via
BCA assay. Samples were separated on 7.5%, 12%, or 15% sodium dodecyl sulfate (SDS)
polyacrylamide (PA) gels (acrylamide; National Diagnostics, Atlanta, GA; Cat #: EC-890) and
transferred to nitrocellulose membranes (BioRad, Hercules, CA; Cat #: 162-0115) in 25 mM Tris,
192 mM glycine, and 20% methanol. After the transfer, membrane strips were blocked in 4% nonfat milk for 1 hour at room temperature and washed with tris –buffered saline + 0.5% Tween-20
(TBS-T) before incubating with primary antibodies overnight at 4°C. Strips were washed with
TBS-T and then incubated with either anti-mouse or anti-rabbit horseradish peroxidase-conjugated
secondary antibodies (Jackson ImmunoResearch, West Grove, PA) for 1h. Strips were washed
with TBS-T and visualized with enhanced chemiluminescence (Pierce/Thermo Scientific,
Waltham, MA).
Antibodies- Anti-STAT5A (L-20; sc-1081; rabbit polyclonal), anti-adipsin (M-120; sc-50419;
rabbit polyclonal), anti-STAT3 (C-20; sc-482; rabbit polyclonal), anti-PPARg (E-8; sc-7273;
mouse monoclonal), anti-PDK4 (C-16; sc-14495; goat polyclonal), and anti-ERK1/2 (C-16; sc93; rabbit polyclonal) antibodies were purchased from Santa Cruz Biotechnology (Dallas, TX).
Anti-adiponectin (PA1-054; rabbit polyclonal) antibody was purchased from Thermo Scientific
(Waltham, MA). Anti-FASN (3180S; C20G5; rabbit monoclonal), anti-ERK1/2 (4695S; 137F5;
rabbit monoclonal), anti-ß-actin (3700; 8H10D10; mouse monoclonal), anti-ATGL (2439; 30A4;
rabbit monoclonal), and anti-MYST1 (4682S; D5T3R; rabbit monoclonal) antibodies were
purchased from Cell Signaling Technology (Danvers, MA). Anti-GAPDH (ab9485; rabbit
polyclonal) antibody was purchased from Abcam (Cambridge, MA).
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RNA analysis- Total RNA from tissue samples was extracted according to TRIzol manufacturer
instructions. RNA from tissue or adipocyte monolayers was purified using the RNeasy mini kit
(Qiagen, Hilden, Germany). Ten microliters of purified RNA were used for reverse transcription
(RT) to generate cDNA according to the Applied Biosystems protocol (Applied Biosystems, Foster
City, CA; Cat #: 4368813). cDNA was quantified using the real-time quantitative PCR (qPCR)
method in a total volume of 10µL (2µL DNA and 8µL reaction master mix) using an Applied
Biosystems 7900HT System with SDS 2.4 software. qPCR was performed using Takara SYBR
premix (Takara Bio USA Inc., Madison, WI, USA) and primers from IDT (Integrated DNA
Technologies, Skokie, IL, USA). Thermal cycling conditions were as follows 2 min at 500C ; 10
min at 950C; 40 cycles of 15 s at 950C and 1 min at 600C; final dissociation stage of 15 s at 950C,
15 s at 600C, and 15 s at 950C. Cyclophilin A (Ppia) and Non-POU domain containing octamer
binding protein (NoNo) were used as reference genes. The following mouse genes were examined
by RT-qPCR: Adiponectin (Adpn), Fatty Acid Binding Protein 4 (aP2), Adipsin (Cfd), Fatty Acid
Synthase (Fasn), and Lysine Acetyltransferase 8 (Kat8). Primer sequences are shown in Table 1.
Statistical analysis- Statistical analyses were performed using GraphPad Prism software (version
8; La Jolla, CA, USA). Differences between groups were calculated using Student’s t-tests and
two-way ANOVA. Results from studies of cultured adipocytes are shown as mean ± standard error
of the mean (SEM). Results were considered statistically significant when p < 0.05.
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Table 4.1. qPCR Primer Sequences
Gene
Cyclophilin A
(Ppia)
Non-POU
domain
containing
octamer binding
protein (Nono)
Adiponectin
(Adpn)
Fatty acid
binding protein 4
(aP2)
Fatty Acid
Synthase (Fas)
Adipsin (Cfd)
Lysine
Acetyltransferase
8 (Kat8)

Primer 1, 5’-3’
CCACTGTCGCTTTTCGCCGC

Primer 2, 5’-3’
TGCAAACAGCTCGAAGGAGACGC

CATCATCAGCATCACCACCA

TCTTCAGGTCAATAGTCAAGCC

AAAAGGGCTCAGGATGCTACTG

TGGGCAGGATTAAGAGGAACA

CCCTCCTGTGCTGCAGCCTTT

GTGGCAAAGCCCACTCCCACTT

GGCATCATTGGGCACTCCTT

ACCACCAGCTGCCATGGATC

CGAGGCCGGATTCTGGG
GAGTCGTCATCCGTCACTCC
CGAGTACTGCCTCAAATACATGA GCCATCCACTTCATACACAGA

4.3 Results
4.3.1 KAT8 is highly expressed in white adipocytes in vivo
To examine the relative tissue distribution of KAT8 in C57BL/6J mice, we assessed its
expression in many tissues, including several adipose tissue depots. As shown in Figure 4.1, KAT8
is expressed in many tissues such as the lungs, heart, and spleen. More importantly, KAT8 is highly
expressed in white adipose tissue (WAT) depots, such as inguinal WAT (iWAT), gonadal WAT
(gWAT), retroperitoneal WAT (rpWAT), and mesenteric WAT (mWAT), but not brown adipose
tissue (BAT). Among adipose tissue depots, KAT8 is most highly expressed in iWAT. This data
suggests a potential role for KAT8 in adipose tissue.
In Drosophila melanogaster, KAT8 is referred to as a male-specific protein. To assess sex
specificity of KAT8 in C57BL/6J mice, we compared expressions of KAT8 between sexes in the
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GI tract (Figure 4.2A), gonads, adipose tissue, and lungs (Figure 4.2B). While there was no male
specificity in any of the tissues KAT8 expression in the small intestines, ovaries, iWAT, and
rpWAT was elevated in female mice compared to males. Lungs, mWAT, and BAT/WAT had
similar expressions of KAT8 in both male and female mice. These data show that KAT8 is not a
male-specific protein in C57BL/6J mice.
Because KAT8 is highly expressed in adipose tissue, it was essential to determine whether
KAT8 was expressed in the adipocytes or stromavascular fractions (SVF) of iWAT and eWAT of
male and female C57BL/6J mice. Adipose tissues were digested and fractionated to isolate
adipocytes and SVF to assess KAT8 expression. Figure 4.3 shows that KAT8 is expressed in both
adipocytes and SVF, but KAT8 is more highly expressed in adipocyte fractions of both male and
female mice. This data also shows that KAT8 expression is more robust in the adipocytes of female
mice versus males. The SVF of iWAT and eWAT contains multiple other cell types and further
studies would be required to determine which cell types express KAT8 within the SVF. Moreover,
this data shows that KAT8 is more localized within the adipocytes. Together, these data strongly
suggest a role for KAT8 in white adipocytes.
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Figure 4.1. KAT8 is highly expressed in white adipose tissue depots and lungs. Select tissues were
harvested from a 27-week old C57BL/6J mouse. Tissue samples were homogenized, and protein
was isolated. 100 µg of total protein per lane were analyzed by Western blotting. gWAT, gonadal
WAT; rpWAT, retroperitoneal WAT; iWAT, inguinal WAT; mWAT, mesenteric WAT; BAT,
brown AT; EDL, extensor digitorum longus; gastroc, gastrocnemius.
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Figure 4.2. KAT8 is highly expressed in WAT tissue depots of C57Bl/6J mice but does not exhibit
male specificity. Tissue samples were subjected to homogenization and protein isolation. 100 µg
of total protein per lane were analyzed by Western blotting. KAT8 expression was assessed in the
adipose tissue depots, gonads, (A) GI tract, and (B) lungs of both male and female C57BL/6J mice.
STAT5A was utilized as an adipose tissue marker. ERK 1/2 was utilized as a loading control. SI,
small intestine; LI, large intestine. (n=1)
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Figure 4.3. KAT8 is highly expressed in adipocytes of C57BL/6J tissue fractions. Adipocytes and
stromavascular fractions (SVF) were isolated via collagenase digestion in iWAT and eWAT
depots of male and female C57Bl/6J mice. 50 µg of total protein per lane were analyzed by Western
blotting. Adiponectin was utilized as an adipocyte marker and ERK ½ as a loading control. (n=2)

4.3.2 KAT8 is nutritionally regulated by diet-induced obesity and fasting
To determine whether KAT8 expression was regulated by diet-induced obesity (DIO),
C57BL/6J mice were subjected to either low-fat (LF) or high-fat (HF) diets for 12 weeks. Inguinal
WAT (iWAT), gonadal/epididymal WAT (g/eWAT), and BAT were harvested and analyzed in
both male and female mice (Figure 4.4). In female mice, KAT8 expression was not regulated by
DIO in either gWAT or iWAT at the protein level (Figures 4.4A and C, respectively). Figure 4.5B
also exhibits no significant transcriptional regulation of Kat8 in female mice after prolonged highfat feeding despite the expected downregulation of fatty acid synthase (Fasn) and adipsin (Adpsn).
In contrast, KAT8 protein expression is upregulated in eWAT and iWAT during prolonged highfat feeding in males (Figures 4.4B and D, respectively). Despite the upregulation of KAT8 at the
protein level, Kat8 mRNA expression is not regulated during high-fat feeding in male mice (Figure
4.5A). These data suggest that KAT8 protein expression is upregulated by DIO.
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To further assess nutritional regulation of KAT8, we examined KAT8 expression in
thirteen-week-old female C57BL/6J mice subjected to either eighteen hours of fasting (Fasted) or
fourteen hours of fasting followed by four hours of ad libitum refeeding with chow (Refed). KAT8
expression was assessed in iWAT, gWAT, rpWAT, BAT, and liver upon harvest. In Figure 4.6,
we observed an upregulation of KAT8 protein expression with refeeding in each of the adipose
tissue depots, but not in the liver of female mice. This upregulation of KAT8 was more pronounced
in iWAT, gWAT, and rpWAT of female mice and more modest in BAT (Figures 4.6A-D).
Although we did not see the expected upregulation of FASN during refeeding, we did observe the
expected upregulation of PDK4 during fasting in the liver (Figure 4.6E). This study indicates that
KAT8 is regulated by fasting and refeeding. Altogether, Figures 4.4-4.6 clearly show that KAT8
is nutritionally regulated in vivo.
4.3.3 KAT8 is a stable protein and does not affect FASN and PPARg turnover in vitro
Current literature suggests that KAT8 interacts with and acetylates FASN to promote
protein degradation of FASN via ubiquitylation [76]. To determine KAT8 and FASN protein
stability, 3T3-L1 cells were treated with cycloheximide (CHX) for indicated time points in the
presence and absence of KAT8. Under basal conditions in the presence of CHX, KAT8 and FAS
expression was unaffected despite the expected decline in PPARg protein expression indicating
that both FASN and KAT8 are relatively stable proteins (Figure 4.7A). Next, a siRNA-mediated
knockdown of KAT8 was performed and 3T3-L1 cells were subjected to CHX treatments. Figure
4.7B shows that FASN expression is unaffected by the loss of KAT8 in 3T3-L1 cells, indicating
that KAT8 does not modulate FASN turnover rates in vitro.
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Figure 4.4. KAT8 expression is significantly upregulated in the eWAT and iWAT of male, but not
female mice following high-fat feeding. Six-week old male and female C57BL/6J mice were fed
either a high-fat (HF) or low-fat (LF) diet for 12 weeks ad libitum before euthanizing and collecting
adipose tissue. Tissue samples were homogenized, and 30 µg of total protein per lane were
subjected to Western blot analysis (n = 6 per condition) for males (B, D) and females (A, C).
Adipsin was utilized as a control for high fat feeding. STAT3 was utilized as a loading control.
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Figure 4.5. Steady state mRNA expression of Kat8 is not significantly regulated in adipose tissue
after high-fat feeding in male and female C57BL/6J mice. Six-week old C57BL/6J mice were fed
either a high-fat (HF) or low-fat (LF) diet for 12 weeks ad libitum before euthanizing and collecting
tissue. BAT, iWAT, and gWAT samples were homogenized and RNA was isolated and purified
from each tissue depot for male (A) and female (B) mice. Each sample was subjected to RT-qPCR
to show gene expression of Kat8, adipogenic markers (Adpn, Ap2, and Fas), and adipokine
(Adipsin). Data was analyzed by unpaired t-tests. * indicates p < 0.05, ** indicates p < 0.01, ***
indicates p < 0.001, and **** indicates p < 0.0001 vs. LF diet (n = 6 per condition). Each sample
was ran in duplicates. Target gene expression was normalized to the reference gene, Cyclophilin
A, and data are plotted as fold change over the LF control.
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Figure 4.6. KAT8 expression is significantly increased in adipose tissue (WAT), but not in liver
of female mice during refeeding. Thirteen-week old female C57BL/6J mice were fed chow diet
and were fasted for either 18 hours, or for 14 hours and refed for 4 hours ad libitum before tissue
collection. KAT8 expression was assessed in the (A) iWAT, (B) gWAT, (C) rpWAT, (D) BAT,
and (E) liver during fasting and refeeding. 75 µg of total protein per lane were subjected to Western
blot analysis (n = 2 per condition).
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Figure 4.7. KAT8 does not affect FAS or PPAR! turnover in 3T3-L1 adipocytes. (A) Fully
differentiated 3T3-L1 cells were treated with CHX and harvested at the indicated time points, and
KAT8 expression was assessed. (B) Fully differentiated 3T3-L1 adipocytes were transfected with
non-targeting siRNA (NT) or KAT8 siRNA for 48 hours prior to harvest and endpoint assessments
were conducted on the cells. Whole-cell extracts were isolated and 50 µg protein per lane were
analyzed by Western blot analysis (n=2 pooled samples/lane). ERK 1/2 was utilized as a loading
control.
4.4 Discussion
Our novel data suggest that KAT8 has a role of importance in adipose tissue. The analysis
of many mouse tissue samples revealed that KAT8 is highly expressed in WAT and lungs. It is not
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surprising that KAT8 is highly expressed in the lungs, as KAT8 has been studied as a target cancer
therapeutic in lung cancer for its ability to suppress p53 activation and regulate G2/M cell cycle
arrest [126]. However, the unexpected findings of the robust expression of KAT8 in WAT of
C57BL/6J mice has not been reported to our knowledge (Figure 4.1). Although KAT8 is a malespecific protein in Drosophila melanogaster [62], this is not the case in C57BL/6J mice (Figure
4.2). Rather, enhanced expression of KAT8 in rpWAT and gonads of female mice could suggest
differential roles of KAT8 in D. melanogaster and mus musculus. However, this requires further
study.
Similarly, robust expression of KAT8 in adipocyte fractions of WAT of male and female
mice further suggests a role for KAT8 in adipocytes (Figure 4.3). Because KAT8 is highly enriched
in WAT depots, we assessed whether KAT8 was regulated in AT during DIO. KAT8 is
upregulated during DIO in male mice at the protein level (Figure 4.4), but not regulated at the
mRNA level (Figure 4.5). These differences between mRNA and protein expression could result
from differences in translational rates, protein degradation, or both [110]. As for sex-specific
differences in KAT8 regulation, they could be due to differing metabolic responses to prolonged
high-fat feeding in C57BL/6J mice [103]. Female C57BL/6J mice have been shown to be more
metabolically healthy, insulin sensitive, and have reduced inflammation despite displaying the
obese phenotype while on HFD [102–104].
The regulation of KAT8 expression in AT by refeeding has not been reported by any other
group (Figure 4.6). Currently, mechanisms by which these effects are mediated are unknown and
require further study. Although we suspected that KAT8 might be mediating its effects via its
interaction with FASN, this now appears unlikely, as CHX studies revealed that the loss of KAT8
in mature adipocytes has no effect on FASN expression or turnover rates [76]. Nonetheless, these
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data all strongly suggest the KAT8 has essential roles in the function and development of adipose
tissue. Our findings demonstrate that (1) KAT8 is highly expressed in adipocytes and adipose
tissue, (2) KAT8 is nutritionally regulated by diet-induced obesity and fasting/refeeding, and (3)
KAT8 has no effect on protein turnover of FASN. Future studies will be needed to determine how
KAT8 functions in adipocytes and how it modulates adipose tissue development.

64

CHAPTER 5. CONCLUDING REMARKS
Our novel studies provide further understanding of adipocyte development and regulation
of two uncharacterized adipocyte proteins. The contribution of MPCs and KAT8 to adipocyte
development and the regulation of these two proteins in mature adipocytes has not been
extensively studied until now. Most studies of MPCs in adipocytes focus on the function of MPCs
in brown adipocytes, rather than white adipocytes. On the contrary, KAT8 has been extensively
studied for its role in histone modification and off-target substrate acetylation, but there is limited
literature on KAT8 regulation or function in preadipocytes or adipocytes. Our studies explore the
function and regulation of both MPCs and KAT8 in adipocytes and adipose tissue during metabolic
dysfunction.
Because MPC protein expression was upregulated during adipogenesis, we expected MPCs
to be required for adipocyte development. MPCs were thought to be required for adipogenesis due
to its requirement for pyruvate transport into the mitochondrial matrix. Surprisingly, in vitro
studies clearly show that the loss in functionality of the MPC complex, via knockdowns and
pharmacological inhibition, has no noticeable effects on adipogenesis in 3T3-L1 cells. Inhibition
of pyruvate transport associated with MPCs did not alter lipid accumulation, adipocyte
development, or expression of adipogenic genes. This suggests that there are other mechanisms
that can compensate for the loss of functionality of the MPC complex, such as pyruvate-alanine
cycling [106]. These findings could also suggest that in the event that MPC functionality is lost,
there are alternative substrates that can bypass the MPC complex, such as alanine, glutamine, and
branched chain amino acids [85,106–108]. The limitation of these studies is that they were only
performed in vitro, and future studies should be performed in vivo.
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On the other hand, the loss of KAT8 in vitro completely inhibited adipocyte development.
One published study has suggested that KAT8 is a negative regulator of adipogenesis [83].
However, our data indicate that KAT8 is a positive regulator of adipogenesis. Our results used the
same model system and were repeated several times so we are confident in our results. In addition,
Gao et. al. reported findings that were contrary to published literature. Unlike MPCs, KAT8
expression was not highly regulated during adipogenesis but was required for adipogenesis. Loss
of KAT8 expression resulted in severely impaired lipid accumulation and adipocyte development
in vitro. However, the mechanism by which KAT8 is mediating its effects is currently unknown.
Since KAT8 plays a role in proliferation, this might be the reason that it is needed for in vitro
adipogenesis, which is dependent on mitotic clonal expansion. If the role of KAT8 is limited to
preadipocyte proliferation, it might play a role in adipogenesis in vivo. Because there are no
mechanistic studies of KAT8 in adipocytes, it is challenging to perform studies to identify its
function(s) in mature fat cells. Nonetheless, it is clear that KAT8 plays an essential role in
adipocyte development and likely impacts adipocyte function in vitro. Future studies will be
required to determine the functional relevance of KAT8 in adipocyte in vitro and in vivo.
In vivo, our novel data demonstrate that MPC1 and MPC2 expression are enriched in
tissues such as BAT, liver, heart, lungs, and kidney. This was expected because each of these
tissues are mitochondria-rich. Despite expression and regulation of MPCs in 3T3-L1 cells, a white
adipocyte model, there was minimal expression in either of the WAT depots. During prolonged
high-fat feeding studies, we confirmed that MPC1 and MPC2 proteins are nutritionally
downregulated in BAT of male mice during DIO. We suspect that this downregulation is due to
decreased thermogenic capacity, but further studies are needed to determine this.

66

Additionally, we show that KAT8 is highly expressed in the adipocyte and SVF fractions
of WAT depots in male and female mice. Our novel data also showed that KAT8 was more highly
expressed in WAT, more specifically iWAT, than in any other tissue in C57BL/6J mice. Coupled
with the requirement for adipogenesis, this further suggests that KAT8 plays a prominent role in
adipocytes. The previously reported male-specific protein (in Drosophila) was not shown to be
male-specific in C57BL/6J mice, but our data did show enhanced expression in female mice in
iWAT and rpWAT. Moreover, our data confirm that KAT8 is nutritionally upregulated by DIO
and refeeding after fasting.
In order to determine mechanisms by which MPCs and KAT8 are mediating their effects,
additional studies are required. To further study MPCs, determination of whether substrate bypass
of the MPC complex or alternative pyruvate transport mechanisms are responsible for
compensating for the loss of MPC complex functionality in vitro will be important. To assess
whether the downregulation of MPCs during DIO is due to decreased thermogenic capacity, we
would need to measure parameters, such as energy expenditure and expression of thermogenic
genes, in the presence and absence of MPCs in a DIO model. To further study KAT8 interactions
in adipocytes and determine a mechanism of action, we could perform RNA-Seq experiments in
the presence and absence of KAT8 expression in adipocytes. Also, the generation of an inducible
adipose tissue-specific knockout of KAT8 in mice would provide a clear insight into the metabolic
phenotype of the loss of KAT8 in vitro and further elucidate the role of KAT8 in adipose tissue.
Although there are currently no mechanistic studies suggesting the role of these proteins in
adipocytes and adipose tissue, these studies further advance the field of adipocyte biology.
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